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PSI        Percentage Splicing Inclusion 
PTB        Polypyrimidine Tract Binding protein 
PPT              Polypyrimidine tract  
qPCR        quantitative real-time PCR 
QKI               Quaking 
RBFOX2      RNA binding protein, fox-1 homolog 
RGD             Arginine-glycine-aspartic acid  
RNA             Ribonucleic acid  
RNAi            Ribonucleic acid interference  
RRM            Ribonucleic acid recognition motif  
RT-PCR        Reverse transcription polymerase chain reaction  
RBP        RNA-binding protein 
RRM        RNA recognition motif 
RNAi        RNA interference 
RNA-seq     RNA sequencing 
RT-PCR        Reverse Transcriptase Polymerase Chain Reaction 
siRNA           Small interfering ribonucleic acid  
snRNP          Small nuclear ribonucleoprotein  
TBST         Tris-Buffered Saline and Tween-20 
TE         Tris/EDTA 
UTR         Untranslated region 
UCSC          University of California, Santa Cruz 
 
Definition  
Paralogues    a pair of genes that derives from the same ancestral gene. 
Orthologues     genes in different species that evolved from a common ancestral gene by   
speciation. 
Abstract 
 
Alternative splicing is an important mechanism for creating protein diversity. Integrins 
are significant in many aspects of cell biology, including cell signalling and interaction 
with the cell matrix. ITGA6 has two different cytoplasmic C-termini (a6A and a6B) that 
shift 100% between stem cells and fibroblasts. The primary aim in this thesis was to 
monitor splicing patterns during development and differentiation integrin subunit 
alpha 6 (ITGA6) to see which alternative splicing events are similarly regulated in fish 
and humans using early zebrafish development. The a6A and a6B integrins had been 
differentially implicated in the expression in the function of breast cancer and cancer 
stem cells. Therefore, the second aim was to monitor splicing patterns for ITGA6 in 
different cancer cell lines and to compare them with stem cell patterns, fibroblast, and 
zebrafish, determining which splicing regulator protein regulates the ITGA6 alternative 
exon. It was confirmed that the ITGA6 alternative exon 25 was activated by MBNL1, 
RBFOX2 and ESRP in cancer cell lines, and PTBP was discovered as a novel regulator for 
ITGA6 splicing that inhibited the exon of ITGA6 in cancer cell line. The third aim for this 
project was to identify the mechanism of splicing of this ITGA6 alternative exon, 
including identifying the PTB binding site that regulates ITGA6. A minigene system was 
established to study the regulation of the ITGA6 alternative exon. The ITGA6 1.3 
minigene positively responded to siRNA mediated depletion of splicing factors in the 
same way as the endogenous gene, indicating this minigene was a good model. The 
alternative exon of ITGA6 was activated by MBNL1 and was inhibited by PTBP, leading 
to more production of ITGA6B. Using this minigene plasmid it was confirmed that PTBP 
inhibited alternative splicing of ITGA6. The last aim of this chapter was to discover the 
PTB binding sites. Through a series of in silico analyses, a binding site for PTB was 
identified downstream of the regulated exon. Surprisingly, loss of this PTB binding site 
actually repressed this splicing event. These data suggest that PTB both activates this 
alternative splicing event through direct RNA-protein interactions, but also more 
strongly represses this exon, possibly through protein interactions with other 
regulatory   factors.                                                                                      .                                                  
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Chapter 1: Introduction 
1.1 Pre-mRNA  
1.1.1 One gene multiple protein  
 
There are approximately 23,000- 30,000 protein coding genes in the human genome 
which produce a huge variety of proteins (International Human Genome Sequencing, 
2004) (Gerstein et al., 2007). Protein-coding genes numbers are significant when we  
take into an account that the human genome is estimated to produce over one million 
different protein species (Nilsen and Graveley, 2010). This means there must be some 
method to amplify information. This occurs via a series of post-transcriptional 
mechanisms. After DNA is transcribed to precursor messenger RNA (pre-mRNA), it is 
modified by splicing, RNA editing, 3'polyadenylation, 5' capping, transcription and 
termination. These processing steps explain the protein complexity from our relatively 
modest number genes figure1.1 (Lander, 2011).  
In individual cells, gene expression is regulated at the RNA level by modification of the 
primary transcript (pre-mRNA) which produces multiple mRNA isoforms from a single 
gene (Kalsotra and Cooper, 2011). This can lead a single gene to encode multiple 
protein isoforms. mRNA variants can encode functionally and structurally different 
proteins. Proteins can also be modified via post-transcriptional modifications including 
phosphorylation, methylation, ubiquitination, glycosylation, etc.) (Wilhelm et al., 
2014). Taken together post-transcriptional modifications with subsequent post-
translational modifications to proteins leads to the massive surplus of proteins over 
protein-coding genes.  
It has been reported that roughly 95% of human genes are subjected to alternative 
splicing. Alternative splicing allows each human gene to generate two to three 
different mRNA isoforms (Djebali et al., 2012). While not all alternative splicing events 
are of functional importance, alternative spicing is a significant mechanism and key for 
posttranscriptional gene expression.  
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1.1.2 Overview of mRNA 
 
DNA-encoded information in eukaryotic under goes several steps of gene expression. 
The Initial stage of eukaryotic gene expression is the process of transcription in which 
the DNA is transcribed to mRNA by RNA polymerase II (Darnell, 2013). All pre-mRNA 
molecules are subject to a series of processing events, which all known as post-
transcriptional modifications, before they leave the nucleus. Post-transcriptional 
processing steps include capping, splicing and polyadenylation (Mandal et al., 2004). 
mRNA capping takes place after nascent RNA is produced by RNA polymerase. A 
methylated Guanine base is added to the 5’ end of the transcript. The function of the 
cap at the 5’ end is to distinguish between mRNAs and other RNA species (e.g. RNA pol 
I and III produce uncapped RNAs). Capping also protects RNA molecules from 
degradation (Mandal et al., 2004).  
Eukaryotic genes consist of introns and exons. Splicing removes introns and joins exons 
in order to produce functional mRNAs. Spliceosomes contain small nuclear 
                                
Figure 1.1:  Multiple mRNAs from a single gene.  Post transcriptional mechanism 
including A) alternative splicing  B) alternative polyadenylation C) RNA 
editing(Siomi and Dreyfuss, 1997) 
Chapter 1                                                                                                                                  Introduction 
 
3 
 
ribonucleoproteins (snRNPs), heterogeneous nuclear ribonucleoproteins (hnRNPs) and 
a large range of auxiliary RNA-binding proteins (Cramer et al., 2001). The next and 
often final stage is of mRNA polyadenylation. Polyadenylation comprises two 
processes, including cleaving mRNA during RNA pol II elongation and adding a poly(A) 
tail to the 3’ end. The function of polyadenylation is to protect RNAs from degradation 
and provide its transfer to the cytoplasm for subsequent translation (Stewart, 2010). 
mRNA processing is thought to occur cotranscriptionally, in which transcription and 
processing are not consecutive, but simultaneous. Following the co-transcriptional 
processing including capping, splicing and polyadenylation, mRNA is exported from 
nucleus to cytoplasm where it eventually serves as templates for protein synthesis  via 
translation (Stewart, 2010). 
 
1.2 Splicing     
    
Precursor messenger RNA (pre-RNA) splicing is one of the most dynamic processes in 
eukaryotic cell biology (McManus and Graveley, 2011). Splicing plays a major role in 
gene expression. Splicing consists of the removal of introns, whilst exons are ligated 
together in order to form mature protein-coding mRNA (Will and Luhrmann, 2011). 
Splicing involves a series of reactions that are catalysed by the spliceosome. The 
spliceosome is one of the most complicated machineries in the cell. There are two type 
of spliceosome.  The major spliceosome is responsible for the removal of introns that 
harbour consensus splice site sequences. The minor spliceosome targets a less 
abundant class of non-canonical intron, which differ in splice sites from the consensus 
ones.  
The spliceosome contains approximately 150-300 proteins and five small nuclear RNAs 
within the  U1, U2, U4/U6, U5 and ribonucleoproteins (snRNPs)—all of which combine 
to create a large complex machine containing RNA and protein (Wahl et al., 2009). The 
snRNPs designated U1, U2, U4/U6 and U5 are the major spliceosome components 
required for spliceosomal formation.  The 5’ and 3’ splice sites (ss) are required for the 
assembly of the spliceosome. The snRNAs catalyse the splicing reaction, and direct 
recruitment to the 5’ and 3’ splice sites (ss) to help define intron/exon boundaries 
(McManus and Graveley, 2011) (Wahl et al., 2009). In humans, CAG/GURAGU (in which 
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R=purines and GU is invariant) is the consensus sequence for the 5’ss, whereas YAG/G 
(in which Y=pyrimidine and AG is invariant) is the consensus sequence at the 3’ss. 
There are also two other components to the 3’ ss, including an upstream 
polypyrimidine tract (PPT), which has a variable length, and a branch point sequence 
containing an adenosine which is usually located 18-40 nucleotides upstream from the 
PPT (Figure 1.2 A) (Will and Luhrmann, 2011).  
The 5’ splice site and 3’ splice site core elements are bound by specific components of 
the spliceosome. U1 snRNA hybridises with the 5ʹss whereas U2 snRNA and the two 
subunits from U2AF recognise the 3ʹss, PPT and branch point (BP) respectively. Splice 
site selection can be influenced by variations in the splice site sequence; splice sites 
which closely resemble the consensus sequence are more efficiently recognised by 
spliceosomal proteins and snRNAs than splice site which have considerable deviations 
from the consensus sequence figure 1.2B (Will and Luhrmann, 2011). 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure1.2: Cis elements that control pre-mRNA splicing. A) The four components of 
the splice site in an intron are the 3’ splice site, polypyrimidine tract, branch point 
and 5’ splice site.  B) Splicing complex formation by exon definition. Spliceosomal 
complexes form along the pre-mRNA during splice site recognition and enable 
commitment to splicing. U1snRNP binds at the 5’ss by base pairing, whereas U2AF 
binds at the 3’ss and polypyrimidine tract. The branch point is bound by U2 snRNA. 
Other RNA-binding proteins including ‘SR’ proteins bind to cis-acting splicing 
enhancers to further help define the correct splice sites. Image redrawn from (Wahl 
et al., 2009)  
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1.2.1 Splicing mechanism   
 
Three major processes constitue the splicing mechanism: spliceosome assembly on the 
pre-mRNA, the splicing reaction per se and ultimate intron release (Moore and Sharp, 
1993).  The splicing reaction itself occurs in two steps, both of which are trans-
esterification reactions (Will and Luhrmann, 2011). The first trans-esterification 
reaction occurs due to a nucleophilic attack by the 2’OH group of the conserved 
adenosine within the branch site, with the conserved guanine of the 5' splice site at 
the exon-intron junction (Moore and Sharp, 1993). As a result, the exon 1-intron 
junction is cleaved, and the lariat intermediate which is still linked to exon 2 is formed 
(Will and Luhrmann, 2011). The second trans-esterification occurs when the 3’OH 
group of the released upstream exon attacks the last nucleotide of the intron at the 
3ss. Consequently, the two exon sequences are ligated together, and the intron 
sequence is released as a lariat structure figure 1.3 (Moore and Sharp, 1993). 
 
 
 
 
 
 
 
 
 
        
 
 
 
 
Figure 1.3: The two steps of the splicing mechanism. Both reactions are 
nucleophilic attacks. In step one an OH group at the branch site adenosine 
attacks the (‘splice donor’) 5’ splice site. In step two the 5’ splice site attacks the 
3’ (‘acceptor’) splice site and thus the intron is removed and the two exons are 
ligated. 
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The spliceosome consist of five distinct intermediate protein complex process called H, 
E, A, B and C that assemble sequentially as in figure 1.4 (Reed, 2000, Wahl et al., 2009).  
Splicing initiates with un-spliced pre mRNA forming H complex, consisting  of pre-
mRNA bound by the non-specific association of a group of RNA-binding proteins called 
hnRNPs (Black, 2003).  After that, E complex forms in which recognition of the 5’ splice 
consensus splice site is driven by U1 snRNP in an ATP-independent manner.  Other 
RNA- binding proteins (including members of the SR protein family )  interact  with  U1 
snRNP (Soller, 2006). In addition to the U1-5’splice site interaction, splicing factor 
1/branch point bound protein (SF1/BBP)   binds to  the branch point and interacts with 
U2 the auxiliary factor (U2AF) heterodimer. U2 auxiliary factor (U2AF) heterodimer 
consists of two subunits:  a 65kDa subunit (U2AF65) which recognizes the 
polypyrimidine tract (PPT) and a 35kDa subunit (U2AF35) which recognizes the 3' splice 
site consensus sequence (Valadkhan, 2007).  
E complex is followed by A complex in which U2 snRNP interacts with the branch point.  
Subsequently, the branch point adenosine is bulged out of the U2snRNP-premRNA 
duplex and is ready to attack the 5ss. The following step involves U4/U6/U5 tri-snRNA 
binding to the spliceosome in order to form the B complex, which promotes the first 
transesterification catalytic step of splicing. Within  complex C, in which the second 
catalytic step also takes place when the upstream 5’ splice site ligates to the 3’ splice 
site in order to splice the exons and  release the intron lariat intermediate (Wahl et al., 
2009).  
Overall the U2, U5, U6 snRNPs and other splicing factors are important in splicing 
reactions as well as other supportive proteins including ATPases, helicases and 
DExD/H-box proteins which drive spliceosome assembly. When splicing is completed, 
the lariat intron is degraded, while the snRNPs are recycled and used in the 
subsequent splicing reactions (Reed, 2000, Soller, 2006, Wahl et al., 2009).  
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1.2.3 The minor spliceosome        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
 Although the majority of eukaryotic introns are removed by the major spliceosome, 
there are a small number of (non-canonical) introns that are removed by a minor 
spliceosome. The minor spliceosome consist of four specific snRNPs called 
U11/U12/U4atac, U6 ATAC and U5 which the latter is the only snRNP shared by both 
types of spliceosomes (minor and major) (Patel and Steitz, 2003). In general terms, the 
function of the minor splicisome is similar to that the major spliceosome. The major 
spliceosomal splices U2-dependent introns which are recognised by U2 snRNP. These 
introns usually start with a GT nucleotide and finish with AG bases. On other hand, the 
minor splicisome recognises U12-dependent introns due to intron recognised by U12 
type. U12 introns typically start with AT and finish with AC nucleotides (Turunen et al., 
2013, Tarn and Steitz, 1996, Yu and Steitz, 1997) 
 
Figure 1.4 : Schematic  diagram showing the splicing reaction  (Wahl et al., 2009) 
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1.2.4 Alternative splicing  
 
The average gene contains approximately 10 introns which need removing from an 
average length of 120kb, to reduce the size to an average of 2kb mRNA after splicing. 
This large number of exons and surplus sequence attests to the remarkable fidelity of 
splicing and also leaves a large margin for variation. Alternative splicing is a process by 
which RNA diversity is generated by joining different combinations of splice sites from 
a single gene. Alternative splicing is now known to have a significant function in gene 
expression. It was estimated that alternative splicing affects 60% of human genes 
(Srebrow and Kornblihtt, 2006). Since then, with developments in bioinformatics 
analysis and advanced sequencing techniques, that estimated percentage figure is now 
increased, such that approximately 95% of multi-exon genes are now thought to 
undergo alternative splicing (Pan et al., 2008). However the proportion of these 
alternative events that are truly functional is not yet established.  
 
Changes to splicing patterns play a significant role in gene expression and the function 
of various proteins. In addition splicing changes can be regulated to play a significant 
role in facilitating responses to changes in external stimuli, for example in CD44, a 
transmembrane glycoprotein (Pan et al., 2008). It has been reported that growth 
factor signalling has an effect on production of CD44 isoforms, specifically inclusion or 
exclusion of variable exon V6, and that this creates a positive feedback as the V6 
containing isoform is more active as a co-receptor for growth factor (Cheng et al., 
2006). 
 
Exon skipping is one of the most prevalent patterns to occur during splicing (Figure 
1.5B) (Reddy, 2007). Like all forms of alternative splicing, exon skipping can lead to a 
change in the reading frame and a truncated protein, or the change can be an in frame 
removal/addition of a number of amino acid residues (Srebrow & Kornblihtt, 2006). 
Another kind of alternative splicing involves mutually exclusive exons; this splicing 
pattern occurs when one exon is retained and one exon is skipped, leading to the 
generation of two different isoforms (Figure 1.5 C)(A. S. Reddy, 2007). The retention of 
an intronic sequence is a relatively rare form of AS in vertebrates but it too can occur 
due to the silencing of splice sites within the intron (Srebrow & Kornblihtt, 2006). Yet 
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another pattern of alternative splicing involves alternative 5’ or 3’ splice sites. This 
leads to deletion of part of the 3’ end of the upstream exon or part the 5’ end of the 
downstream exon (Pan et al., 2008) (Figure 1.5 E,F). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5: The different kinds of alternative splicing events (see text for details). 
Image was redrawn from (Srebrow & Kornblihtt, 2006). 
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1.3 RNA-protein interaction:  
 
RNA-binding by RNA-binding proteins (RBPs) regulate the metabolism of RNA in 
eukaryotes (Anko and Neugebauer, 2012). RBPs contribute to all nuclear mRNA 
processing steps including capping, splicing, and polyadenylation as well as mediating 
the transport of mRNAs from the nucleus to the cytoplasm and regulation of their 
translation. RBPs form large ribonucleoprotein complexes (RNPs) on the RNA in order 
to regulate different steps of RNA metabolism. RNPs are classified according to 
whether they bind in the nucleus or in the cytoplasm and are thus called 
heterogeneous nuclear RNPs (hnRNPs) ,which also form on pre-mRNA, or messenger 
RNPs (mRNPs) respectively (Janga and Mittal, 2011).There are a variety of motifs that 
bind to RNA including RNA recognition motifs (RRMs), K homology (KH) domains and 
zinc fingers which help to facilitate and control the localization and processing of RNA. 
Figure 1.6 summarises the mechanisms controlled by RBPs in a cell (Janga & Mittal, 
2011). 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
         
Figure 1.6: RNA-binding protein processing in various post-transcriptional 
processes at different locations in eukaryotic cells. RBPs are involved in 5 major 
processes that are represented by red circles. 1) RBPs play a major role in splicing 
of mRNA in the nucleus. 2) After that mRNA export from nucleus to the cytoplasm 
by various RBPs. In cytoplasm, 3) RBPs contribute to mRNA localization in 
compartments such as the mitochondria. 4) RBPs are also responsible for RNA 
stability and lead to degradation. 5) RBPs are also involved in translational control. 
Image adapted from (Janga and Mittal, 2011).   
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1.4 The regulation of splicing 
 
 There are several factors that affect splice site choice, including cis-acting elements 
and trans-acting factors (Smith and Valcarcel, 2000). Splicing patterns are affected by 
the expression of RNA-binding proteins that can be expressed at different stages of 
development and in different tissues. Other factors which can directly affect the 
splicing outcome include the rate of transcriptional elongation, epigenetic factors and 
the formation of secondary structures within RNA. Secondary structure, which forms 
within the pre-mRNA, has a significant impact on splicing activation. It can have a 
similar effect on splicing as the way that RNA-binding proteins prevent sequence 
recognition (Warf and Berglund, 2010). Secondary structures of RNA can also exert 
effects on splicing by changing the distance between auxiliary elements and splice 
sites. Epigenetic factors, including histone modifications, can influence splicing 
decisions. Histones interact with the snRNP as a complex during co-transcriptional 
spliceosome assembly and this facilitates the correct assembly of the pre-spliceosome 
(Luco et al., 2011). 
 
Although the regulation of alternative splicing is complicated, the improvement and 
development of technology including high throughput sequencing and advances in 
bioinformatics analysis have facilitated the identification of splicing regulatory motifs 
(splicing code), which includes all binding sites for RNA-binding splicing repressors and 
activators within a pre-mRNA, as well as the splice sites themselves.  
 
1.5Cis elements: splicing enhancers and silencers 
1.5.1 Strength of splice site and position  
 
Strength of splice sites can be quantified as the degree of complementarity between 
splice sites and U1 and U2 snRNAs.  In general, constitutive exons which are always 
included into the mature mRNA transcript have strong splice sites whereas alternative 
exons are flanked by weak splice sites.  The development computer programs have 
facilitated the predication of the strength of splicing sites (Smith and Valcarcel, 2000).    
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1.5.2 Cis- elements activators and repressors 
 
Although the strength of splice sites has significant effect on splice site choice, cis-
acting sequences near regions of alternative splicing are also extremely important in 
splice site choice. These sequences can form binding sites for trans-acting factors 
(Smith and Valcarcel, 2000). Cis-acting elements include splicing enhancers, which can 
be either exonic splicing enhancers (ESE) or intronic splicing enhancer (ISE); and 
silencers, which can be either exonic splicing silencers (ESS) or intronic splicing 
silencers (ISS). Generally, enhancers support weak alternative splice sites and assist 
spliceosome and trans-acting factors. ESS and ISS recruit splicing repressor proteins. 
Both silencer and enhancer sequences play a significant role in recognising both 
constitutive and alternative exons figure 1.7 (Matlin, Clark, & Smith, 2005)(Martinez-
Contreras et al., 2007). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.5.3 Trans-acting RBPs 
 
Trans-acting RNA-binding protein factors can significantly affect splicing depending on 
the concentration and localisation of the RNA-binding protein. One group of trans-
acting factors acting at cis elements are the SR protein family that play a major role in 
binding splicing enhancers (acting at ESEs) in a concentration- and phosphorylation-
 
Figure 1.7:  Sequence elements that affect splicing include both splicing 
enhancer (ESE/ISE) and splicing silencers (ESS/ISS). Image modified from 
(Srebrow & Kornblihtt, 2006) 
Strong weak 
ESE ESS
ISE ISS
Strong Strong 
AD DA
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dependant manner (Smith & Valcarcel, 2000). Long non-coding RNA (IncRNA) have also 
been reported to influence splicing by modulating the phosphorylation of SR-proteins 
(Tripathi et al., 2010). The two most recognised families of trans-acting factors that 
have an effect on recognition of splicing silencers or enhancers are the SR proteins and 
heterogeneous ribonucleoproteins (hnRNPs) (Tripathi et al., 2010). These proteins are 
expressed at varying levels in different tissues. In contrary to SR proteins, hnRNPs are 
mostly seen as splicing regulators that bind RNA to repress splicing (although there are 
many exceptions). HnRNP proteins can contain RRM domains, RGG (arginine-glycine-
glycine) domain and KH (hnRNP K homology) domains as well as others.  The presences 
of hnRNPs on the RNA affect the ability of the core splicing machinery to engage with 
splice sites (Martinez-Contreras et al., 2007).    
 
SR proteins have RRM regions that bind to RNA and auxiliary regions rich in RS 
(arginine-serine) dipeptides that are thought to be mostly involved in protein-protein 
interactions that assist assembly of functional splicing complexes (Tripathi et al., 2010). 
When SR proteins bind to sequences within exons, they act to recruit components of 
the spliceosome and thus to activate splicing. There is no clear distinction, however, as 
RNA-binding proteins of either class (hnRNP or SR) can act as activators or repressors 
which either inhibit assembly or activity of spliceosomal components at the splice site. 
Furthermore, an individual SR protein or hnRNP can act as a repressor or as an 
activator depending on its binding location in an alternative exon (Martinez-Contreras 
et al., 2007). 
 
 
1.6 Other factors that affect splicing 
1.6.1 Intron/exon structure 
 
There are other factors which might affect splice site recognition including the 
structure of introns and exons (Sterner et al., 1996).  Effects of Introns and exons on 
splice site recognition can be based on their size. When intron size is small, the splice 
sites are recognised across the intron. This is called intron definition. When the intron 
is long, the splice sites are recognised across the exon, this is called exon definition. 
There are a variety of intron size including eukaryotes and human cells. The average 
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exon size in the human is roughly 170 base pairs, whereas the average intron size is 
11,000 base pairs (Sakharkar et al., 2004) (Berget, 1995, Sterner et al., 1996).             
 
1.6.2 RNA secondary structure 
 
RNA structure has significantly impact on splicing. Usually RNA is single stranded; 
however it can fold back in order to adopt secondary and tertiary structures that can 
involve up to hundreds of nucleotides (Buckanovich and Darnell, 1997). RNA structure 
can affect the outcome of pre-mRNA splicing by inhibiting or activating spliceosomal 
assembly. Secondary structures forming within the pre-mRNAs, can have an effect on 
splicing similar to RNA-binding proteins so on to prevent sequence recognition (Warf & 
Berglund, 2010). RNA secondary structures also exert an effect on splicing by changing 
the distance between auxiliary elements and the splice sites such as survival  motor 
neuron 2 (SMN2)(Buckanovich and Darnell, 1997).  
1.6.3 Other factors effect on splicing  
 
Transcription is another factor  that affects splicing (Wang and Cooper, 2007).  Splicing 
is influenced by the speed of transcription, whether the elongation is rapid or slow. If 
the elongation of transcription is rapid, alternative exons will not be recognised before 
downstream competing exons are transcribed, and so will be skipped. If transcription 
is slow,  alternative exons may be recognised by spliceosomes and will be included.   
Epigenetic factors, including histone modifications, can influence splicing decisions 
through affecting transcription. Histones interact with snRNP complexes during co-
transcriptional spliceosome assembly and this facilitates the correct assembly of the 
pre-spliceosome (Luco, Allo, Schor, Kornblihtt, & Misteli, 2011). 
 
Although many RNA-binding proteins are ubiquitously expressed, a variety of tissue-
specific RNA-binding splicing regulators have been identified including neuro-
oncological ventral antigen NOVA1, polypyrimidine tract-binding protein PTBP1, FOX 
protein (RBFOX) and muscleblind (MBNL) protein (Singh et al., 2004). To add further 
complexity, most of these important splicing factors fall into multi-gene families made 
up of several paralogues. 
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1.6.3.1 PTB family proteins  
 
Polypyrimidine tract-binding protein (PTBP1) and its homologues form one of the most 
significant RNA-binding protein families that have been studied in mammals (Valcarcel 
and Gebauer, 1997a). The prototypical member is known as PTBP1 or HnRNPI, and 
generally functions as a splicing repressor. PTB proteins also function in a large number 
of diverse cellular processes including polyadenylation, mRNA stability, mRNA 
localization and translation (Sawicka et al., 2008b). PTBP binds to splicing silencers, at 
pyrimidine rich motifs such as UCUU or CUCUCU in the RNA, to mediate splicing 
repression of many alternatively spliced pre-mRNAs (Noiret et al., 2012). PTB sites are 
highly overrepresented upstream of brain-specific exons, implying that down-
regulation of PTB in brain depresses these exons and causes their brain-specific 
inclusion (Castle et al., 2008, Cheung et al., 2009). In some cases, PTB repression is 
mediated by a single silencer; however, in the majority of cases, multiple PTB binding 
sites are present. In vertebrates, PTBP1 is widely expressed and belongs to a family of 
RNA-binding proteins including two paralogs, PTBP2 and PTBP3, which are expressed 
in a more tissue-restricted manner (Noiret et al., 2012). PTBP2 (previously known as 
nPTB or brPTB) is expressed mainly in neurons, but also in testis and at lower levels in 
skeletal muscle. On the other hand, PTBP3 (also known as ROD1) is mainly expressed in 
embryonic and adult hematopoietic organs (Sawicka et al., 2008). The three PTBP 
paralogues have a >70% amino acid sequence identity and a common arrangement of 
four RRM-type domains (Noiret et al., 2012). Furthermore, they have a functional link 
in the sense that they act as repressors of at least some exons (Noiret et al., 2012). 
 
1. 6.3.2 RBFOX family proteins:  
 
Another significant RNA-binding proteins that play a major role in alternative splicing 
regulation are called RBFOX (Gallagher et al., 2011). Like the PTBP proteins, The RBFOX 
family has three members: RBFOX1, RBFOX2 and RBFOX3, that have similar RNA-
binding domains and are conserved between flies and men (Damianov and Black, 
2010). The RBFOX proteins are among the most sequence-specific RNA-binding 
proteins known, binding to the hexanucleotide UGCAUG. RBFOX proteins display the 
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classic asymmetric splicing activity of many splicing factors; alternative exons are 
repressed by RBFOX-binding directly upstream of the exon and RBFOX proteins 
enhance exon recognition when binding downstream of the exon (Venables et al., 
2009). Thus RBFOX splicing regulation can be exquisitely controlled by placement of its 
binding sites either upstream or downstream of alternative exons. RBFOX proteins 
regulate alternative splicing in a tissue-specific manner including in neurons and 
muscle where they are highly expressed. RBFOX2 has also been defined to regulate 
splicing in embryonic stem cells and embryos (Venables et al., 2013). RBFOX has been 
reported to play a significant role in disease including cancer and autism by affecting 
alternative splicing. Comparing RBFOX1 expression in normal brain tissues and autism 
samples, it was concluded that RBFOX1/2 are likely implicated in Autism (OMIM 
database *605317 and The Autism Genome Project). RBFOX also has been reported to 
have a significant role in cancers including breast and ovarian cancer where a large 
program of alternative splicing was found concomitant with down regulation of 
RBFOX2 (Venables et al., 2009) 
 
1.6.3.3 The ‘Muscleblind’ MBNL family:  
 
Muscleblind (MBNL) is another of the best characterised and most important RNA-
binding proteins (RBPs) that plays a major role in regulating alternative splicing (Ho et 
al., 2004). Like the other RBPs discussed above, the MBNL family has three members: 
MBNL1, MBNL2 and MBNL3, which have nearly identical RNA-binding domains (Ho et 
al., 2004). Like RBFOX, MBNL acts as an activator or as a repressor based on its binding 
position (downstream or upstream of the exon respectively). MBNL regulates AS in 
specific tissues including skeletal muscle, cardiac muscle and the nervous system (Han 
et al., 2013). It has also recently been shown that MBNL down regulation is essential 
for embryonic stem cell derivation and subsequent MBNL upregulation is needed for 
re-differentiation (Han et al., 2013; Venables et al., 2013). MBNL plays a significant role 
in diseases including muscular dystrophy. (Fardaei et al., 2002) appear that there was a 
connection between MBNL and Myotonic dystrophies (DM1) and (DM2). DM1 occurs 
primarily due to an expansion of CTG repeats in DMPK 3’UTR whereas DM2 results 
from an intronic CCTG expansion in another gene called ZFN9. Muscleblind has 
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significant impact in both DM1 and DM2 due to its sequestration at CUG expanded 
repeats which localise to nuclear foci in both diseases  (Fardaei et al., 2002; H. Jiang, 
Mankodi, Swanson, Moxley, & Thornton, 2004). The resulting reduction in the normal 
function of MBNL1 is thought to underlie DM1 pathology. 
 
1.6.3.4 Epithelial Splicing Regulatory Proteins (ESRPs)  
 
Epithelial Splicing Regulatory Proteins (ESRPs) are RNA-binding proteins that have 
significant roles in regulating alternative spicing events associated with epithelial cells 
(Ishii et al., 2014). The ESRP family includes ESRP1 and ESRP2 which are highly 
conserved paralogs containing three RNA Recognition Motif (RRM) domains (Warzecha 
et al., 2010a).  ESRP1 and ESRP2 are involved in epithelial-mesenchymal transition 
(EMT) by maintenance of epithelial cell-specific isoforms. ESRP1 and ESRP2 down 
regulation are essential for EMT progression in a mammary epithelial cell line. It has 
been reported that ESRPs bind to UG-rich motifs. ESRPs regulate alternative splicing 
expression in epithelial cell and cancer cells (Ishii et al., 2014).  
1.7 Alternative splicing in ITGA6 Integrins  
 
Previous results by Julian Venables  data ((Venables et al., 2013b). showed that both 
MBNL and RBFOX control ASE in 15 genes including ITGA6 during stem cell 
differentiation. My project focused on ITGA6 protein to study in depth how alternative 
splicing is regulated RNA-binding proteins. In this section I will review the latest finding 
an integrin including the alternative splicing of ITGA6.   
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1.8 Integrins  
 
Integrins are a large family of heterodimeric cell surface glycoprotein receptors that 
mediate the attachment between a cell and its surroundings including the extracellular 
matrix (ECM) (Barczyk et al., 2010). Integrin dimers are formed by the association of an 
alpha and a beta subunit. There are 18 known α subunit genes and 8 known β subunit 
genes (de Melker and Sonnenberg, 1999, van der Flier and Sonnenberg, 2001). Integrin 
heterodimers are formed by non-covalent association of α and β subunits that each 
straddles the cell membrane through a single-pass, type I, transmembrane protein 
domain (de Melker & Sonnenberg, 1999). Each integrin subunit consists of three major 
domains: the large extracellular domain, the single membrane-spanning 
transmembrane domain and the intracellular cytoplasmic tail domain (van der Flier & 
Sonnenberg, 2001). The integrin extracellular domain functions by binding proteins in 
the extracellular environment, while the intracellular cytoplasmic tail domain interacts 
with the intracellular environment. The integrin family plays a significant role in 
controlling biological and cellular functions such as cell adhesion, migration, 
proliferation, cell differentiation and apoptosis by assembling the actin cytoskeleton 
inside the cell and modulating the signal transduction pathway arriving from outside 
the cell (van der Flier & Sonnenberg, 2001).  
 
There are various ways of categorizing integrins based on either their ligand-binding 
properties or their subunit compositions. The extracellular domains of the α and β 
integrins play major roles in the specificity of integrin binding to the extracellular 
matrix (ECM) components (i.e. collagens, fibronectins and laminins) (Figure 1.8) 
(Barczyk et al., 2010). Table 1.1 shows the ligand specificity of different integrins. One 
subfamily of the integrins, which includes a1b1, a2b1, a10b1 and a11b1, are the major 
collagen receptors, whereas the integrin a3b1, a6b1, a6b4 and a7b1 subunits 
represent the primary laminin receptors (Johnson et al., 2009). The major fibronectin 
receptors are formed by integrins, a5b1, a8b1, aIIbb3, and the avb. This group binds 
the arginine-glycine-aspartic acid (RGD) cell adhesion sequence, which commonly 
appears in extracellular matrix (ECM) 15 components. Nevertheless, there are certain 
integrins that bind to the same extracellular ligands with different affinities, e.g., 
integrin α1β1, which binds to collagen and laminins (Johnson et al., 2009). 
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Figure 1.8: Schematic representing the classification of the integrin family of 
heterodimers, Image adapted from (Barczyk et al., 2010) 
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Table 1.1: Classification of integrins. From (Reddy and Mangale, 2003). 
Family β 
subunit 
α 
subunit 
αβ 
complex 
Receptor I 
domain 
Ligand RGD 
recognition 
Distribution 
VLA 
proteins 
β1 α1 α1β1 VLA-1 + – ? Ubiquitous 
  α2 α2β1 VLA-2 + L, C ? Ubiquitous 
  α3 α3β1 VLA-3 − C, Fn, 
entacin 
? Ubiquitous 
  α4 α4β1 VLA-4 − Fn, 
VCAM-1 
− Ubiquitous 
  α5 α5β1 VLA-5 − Fn + Ubiquitous 
  α6 α6β1 VLA-6 − L RGD Ubiquitous 
  α7 α7β1      
  α8 α8β1   Fn, Vn, 
Tn 
  
  α9 α9β1   Tn  Epithelial cells 
      Fn, Vn  Muscle cells 
  αv αvβ1    +  
 
Leukocytes 
proteins 
 
β2 
 
αL 
 
αLβ2 
 
LFA-1 
 
+ 
 
ICAM-1, 
-2, -3 
  
Leukocytes 
  αM αMβ2 MAC-1 + C3b, Fb, 
ICAM-1 
− Neutrophil, 
monocyte, 
LGL 
  αX αXβ2 P150, 95 + C3b, LPS − M, monocyte 
  αD αDβ2  + ICAM-3 − M 
 β7 α4 α4β7      
  αH αHβ7 LPAM-1  Fn, 
VCAM-1 
 Lymphocytes 
  αE αEβ7  + E-
cadherin, 
adhesion 
 Lymphocytes 
 
Cytoadhesin 
 
β3 
 
αv 
 
αvβ3 
 
Vitronectin 
 
− 
 
Vn, Fb, 
Fn, OPN 
 
+ 
 
Ubiquitous 
      VWF, Tn, 
Thr 
  
  αIIb αIIbβ3 GpIIb/IIIa  Fb, Fn, 
VWF, Vn 
+ Platelets 
 
Other 
combination 
 
β5 
 
αv 
 
αvβ5 
   
Vn, Fn 
 
+ 
 
Ubiquitous 
 β6 αv αvβ6   Fn, Tn ? Lung-
epithelial cells 
 β8 αv αvβ8   Vn +  
 β4 α6 α6β4   L + Epithelial cells 
 
Chapter 1                                                                                                                                  Introduction 
 
21 
 
1.8.1 Integrin structure  
1.8.1.1Extracellular domains  
 
Integrin extracellular domains consist of more than 700 amino acid residues for the α 
subunit and 1000 amino acid residues in their β subunits (Reddy and Mangale, 2003). 
The subunits are organised in order to form a globular ligand-binding N-terminal head 
that ‘stands’ on two long and extended C-terminal ‘legs’ (Reddy and Mangale, 2003). 
The C-terminal legs link to the cytoplasmic and transmembrane domains of each 
subunit figure 1.9A (Barczyk et al., 2010). The extracellular domain of the α subunit 
consists of seven repeated homologous segments (of approximately 60 amino acids) 
that fold into a seven-bladed β propeller ‘head’ domain and two ‘calf’ domains (van 
der Flier & Sonnenberg, 2001). In addition, half of the α subunits have an extra 
independently folding domain termed the I ’inserted’ or ‘A’ domain, of approximately 
200 amino acids (van der Flier & Sonnenberg, 2001). The I-domain contributes to 
ligand binding, and similar domains are also found in trimeric G protein α subunits and 
in small G proteins (Reddy and Mangale, 2003).  
 
The extracellular parts of the β subunits also contain an I-like domain and these too 
play a significant role in integrin ligand binding. I-domains, which are found in both α 
and β subunits, have a conserved “metal ion-dependent adhesion site” (MIDAS). The 
MIDAS contributes to protein ligand binding with divalent metal cations (Mg2+). 
Integrin ligand binding alters the coordination of the metal ion and also shifts the I-
domains from a resting to an open and active conformation; increasing ligand affinity 
and integrin activation occurs as a result (Reddy and Mangale, 2003) figure 1.9B. 
Taking together, the divalent cations binding sites appear in the C-terminus in four or 
three repeats and these appear to mediate integrin ligand binding (van der Flier and 
Sonnenberg, 2001).  
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Figure 1.9: Integrin structure. A) Primary structure of integrin α and β 
subunits. Domains 1-7 represent the homologous repeats in the α subunit. 
Stars represent divalent cation-binding sites (Mg2 as orange star, and Ca2 as 
grey stars). Green represents the conserved domain in the β subunit. The grey 
bar represents the plasma membrane. B) Integrin secondary structure. My 
project concerns alternative splicing of the cytoplasmic portion of the alpha 
subunit that starts with the sequence GFFKR (lower case). Figure from 
(Barczyk, Carracedo et al. 2010). 
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1.8.1.2Cytoplasmic domains  
 
The integrin cytoplasmic domain is generally much shorter than the extracellular 
domain, being about 20-50 residues in the α subunits and variable in the β subunits 
between 15 to 65 amino acid residues with the exception of β4 subunits which consists 
of approximately 1000 amino acids (Calderwood et al., 2003).The crystal structure of 
the cytoplasmic domain has not been resolved at high-resolution, but the cytoplasmic 
domain structure has been determined by nuclear magnetic resonance (NMR). Integrin 
β cytoplasmic tails are highly homologous, while integrin α cytoplasmic tails are 
strikingly divergent (Berman et al., 2003). GFFKR and HDR(R/K)E are conserved 
sequences next to the transmembrane region that form a salt bridge between the α 
subunit at arginine (R) and a β subunit at aspartic acid (D) respectively to help 
assemble and stabilise the heterodimer (Sastry and Horwitz, 1993). Within β subunit 
tails, there are two well-defined motifs, including a membrane proximal NPxY and a 
membrane distal of the NxxY motif (de Melker & Sonnenberg, 1999). These motifs bind 
proteins that contain a phosphotyrosine–binding domain and they act as binding sites 
for multiple integrin binding proteins, such as talin and the kindlins figure 1.10 (de 
Melker & Sonnenberg, 1999). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.10:  Domain structure of α and β subunits in cytoplasmic tail of 
integrins. β subunit binding sites for multiple integrin binding proteins including 
talin are shown in red. Image adapted from (Morgan et al., 2007). 
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1.8.3 Integrin cytoplasmic domains and cell signalling  
 
It has long been known that integrins function as receptors which form a link between 
the ECM and cytoplasm of a cell. Integrins are involved in various functions, including 
signal transduction (Sastry & Horwitz, 1993). Integrins have advantages over other cell 
receptors in that they are able to shift between high and low-affinity ligand binding 
states. Integrin cytoplasmic domains play major roles in transducing two types of 
signalling (Calderwood et al., 2003; Sastry & Horwitz, 1993). The first type, which is 
called outside–in signalling, transmits signalling from ECM to the cell. This occurs due 
to integrin binding to extracellular ligands which lead to changes in the conformation 
of the integrin. Many ligands are multivalent, this causes to Integrins to cluster (Askari 
et al., 2009). Taken together, these events combine and lead to intracellular signals. 
This has a significant impact on modulation of cellular responses, including gene 
expression, proliferation and cytoskeletal organization (Askari et al., 2009). The second 
type of signalling, which is called inside-out signalling, plays a major role in cell 
physiology. Inside-out signalling affects the specificity and affinity of integrins for their 
extracellular ligands (Sastry & Horwitz, 1993). This occurs due to conformational 
changes that are induced in the integrin heterodimer. Integrin cytoplasmic domain 
tails bind with a huge number of cytoskeletal and signalling proteins including talin and 
kindlin which play a major role in separating the cytoplasmic tails which leads to 
integrin activation(Luo, Carman, & Springer, 2007). Figure 1.11 summarises the 
mechanism of integrin signalling.  
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Figure 1.11: Modes of integrin signalling: A shows inside-out signalling.  B show 
outside-in signalling.  Image redraws from (Askari et al., 2009) 
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1.8.4 α subunits in the cytoplasmic domain:  
 
Integrins are composed of α and β subunits in a finite but large number of different 
combinations which are involved in different kinds of cell–cell and cell-matrix 
interactions (Shaw, Turner et al. 1995). The α subunit in cytoplasmic domains are 
conserved in different species with only weak overall homology between the different 
genes. Integrin α3 and α6 cytoplasmic domains are good examples which have been 
studied. It has been reported that α3 and α6 cytoplasmic domains have highest 
homology among the alpha domains (Sastry & Horwitz, 1993). The GFFKR motif just 
adjacent to the membrane is the most strikingly conserved part of the α cytoplasmic 
domains. The α7 cytoplasmic domain is the longest α cytoplasmic domain with 77 
amino acid residues. The α7 cytoplasmic has several short regions of homology with 
other protein such as tyrosine phosphatase. Taken together, α3, α6 and α7 have 
shared motifs in their cytoplasmic domains (Sastry & Horwitz, 1993) . 
1.9 Integrin α6 (ITGA6)  
 
The subject of this  project, the integrin α6 subunit gene is located on chromosome 2 
at 2q31.1 with a total length of 78870 bp (Pulkkinen et al., 1997).  Integrin α6 does not 
dimerise with all beta variants. Integrin α6 mostly combines with two specific β 
subunits α6β1 and α6β4 and both are receptors for the laminin family of extracellular 
matrix proteins (Hogervorst et al., 1993). It has been found that α6β1 is expressed in 
platelets, epithelial cells and several of other cell types. α6β1 is also involved in 
adhesion (Hogervorst et al., 1993). α6β4 integrin is present in various epithelial tissues, 
endothelia and peripheral nerves. α6β4 is also present in the hemidesmosomes of 
epidermal cells which strongly suggested a function of α6β4 in adhesion of cells to the 
extracellular matrix (Hogervorst et al., 1991). ITGA6 is implicated in cancer cells and 
serves as a signalling receptors that triggers signalling cascades that enhance survival, 
invasion and metastasis (reviewed in Mercurio et al., 2001). 
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The two forms of α6 integrin studied heavily are the α6A and α6B mRNA splice variants 
(Figure 1.12). These two isoforms have distinct cytoplasmic domains. Both α6A and 
α6B consist of a large extracellular domain (991 amino acids) and a transmembrane 
domain (23 amino acids) but they differ in their cytoplasmic domains (36 amino acids 
for alpha and 54 for beta) (Hogervorst et al., 1993). The CFFKR sequence is identical in 
both α subunits encoded by either of the α6A or α6B specific exons which then diverge 
downstream figure 1.12 (Hogervorst et al., 1991). The A and B forms are differentially 
expressed throughout the body, however a mouse deleted for the alternative exon 
expressed the  B (exon skipped)  form everywhere surprisingly was fertile and normal 
with just slight quantitative differences in ex vivo assays (Gimond et al., 1998). A role 
for ITGA6 in cancer was suggested as they serve as signalling receptors that triggers 
signalling cascades that enhance survival, invasion and metastasis (reviewed in 
Mercurio et al., 2001). ITGA6 was found to be necessary for tumorigenicity of  a stem 
cell like population within the MCF-7 cell line (Cariati et al., 2008) and it also regulated 
glioblastoma stem cells (Lathia et al., 2010). It was also found that α6 integrin high 
expression is a biomarker in breast cancer cells. α6 subunit signalling regulates the 
processes in tumourigenes including proliferation and metastasis, thus suggesting the 
two splice variants of α6 integrin have specific functions. Taking together these studies 
raise the importance of definition how alternative splicing of ITGA6 is regulated. 
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Figure 1.12: The Two alternatively spliced forms of the ITGA6 genes showing the 
last three exons and the peptide sequences of the alternative C termini 
produced.  a) ref sequences of structure of the two  for ITGA6  isoform b) The two 
alternatively spliced forms of ITGA6 , peptide in black is common between the two 
isoforms a&b.  
 
 
-NCBIGene gene 3655 Ref seq
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 1.10 Research aims and Hypothesis  
 
The preliminary data prior to starting this thesis suggested the following hypotheses: 
 Since the original papers showed a splicing difference between fibroblasts and 
stem cells. We hypothesised that these splicing differences might be regulated 
during development in whole animals, and also modelled in other cell types.  
 The original work indicated that the ITGA6 splicing pattern was controlled by 
two nuclear RNA-binding proteins RBPs (MBNL & RBFOX). We hypothesised 
there might be other RBPs that control this splicing choice, and these RBPs 
might work by direct binding to ITGA6 mRNA. 
 Previous studies showed that RBPs binding downstream of a regulated exon 
usually activated (which include alternative exon)  ,whereas RBP binding 
upstream inhibited splicing( which exclude alternative exon) . We hypothesised 
that PTBP binding sites identified in sites downstream of the ITGA6 regulated 
exon might be inhibitory.  
 
1.10.1 Aims: 
 To monitor splicing patterns for ITGA6 in development. 
 To monitor splicing patterns for ITGA6 in different cell lines.  
 To determine which RBPs control ITGA6 alternative splicing  
 To identify the PTBP binding site which inhibits the ITGA6 alternative exon, and 
if this is downstream of the regulated exon.  
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Chapter 2:  Investigation of orthologues of stem cell 
regulated exons in zebrafish   
2.1 Introduction 
 
Alternative splicing plays an important role in the gene function and in complex 
organisms, such as mammals. Alternative splicing is implicated in germ cell 
development including stem cell and fibroblast differentiation. Recently, data by 
Venables et al (2013)  determine alternative splice events that were important for 
stem cell differentiation. It was shown that a large portion of alternative splicing 
changes during fibroblast differentiation from stem cells (Venables et al., 2013b). This 
research employed  high-throughput RT-PCR with a RefSeq database, which facilitated 
the identification of alternative splicing events that  changed in the full spectrum of 
high and low gene expression (Venables et al., 2013b). The technique started with a list 
of 81 genes including ITGA6 that had alternative splicing events in human tissue. Those 
alternative splicing events were controlled by the MBNL and RBFOX regulation factors. 
ITGA6 with nine genes, including PLOD2, CLSTN1, ATP2A1, PALM, KIF13A, FMNL3, 
PPIP5K1, MARK2 and FNIP1, which showed alternative splicing events between stem 
cells and fibroblasts, were conserved in evolution (Figure 2.1). Most of these 10 genes 
were subject to gene duplications prior to vertebrate radiation, and the alternative 
exons appeared ‘shortly’ beforehand (Venables et al., 2013b). This chapter build on 
data generated in (Venables et al., 2013)  and takes an evolutionary approach to 
further investigate these genes. 
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To conduct this study, it was important to find a good model. The zebrafish has been 
reported as an excellent vertebrate model system for investigating alternative splice 
events that are similarly regulated in both fish and man. The rationale is that 
conserved regulated alternative splicing events are likely to be extremely important for 
the differentiation and development of the body plan of all vertebrates including man; 
thus, these events will likely have medical significance.  
 
High-throughput RT-PCR is the gold standard technique for identifying alternative 
splicing changes. Based on(Venables et al., 2013) data, primers to detect orthologous 
splicing events in zebrafish were designed using sequences identified by Philippe Fort, 
from the CRBM, Montpellier, for the presence or absence of both of two predicted 
isoforms for the 10 genes. The conserved splice events (KIF13 and ITGA6) were studied 
during the first two days of zebrafish development. ITGA6 was one of the 10 ASEs that 
                          
 
Figure 2.1: A conserved regulated program of alternative splicing in germ layer 
specification (Venables, Lapasset, et al., 2013) 
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shifted from one isoform to another during stem cell differentiation and zebrafish 
embryogenesis. Thus, these isoforms are likely to be of importance for differentiation, 
development and fundamental cellular processes. 
 
 
 
2.2 Aims: 
 
 To Investigate alternative splicing events of 10 genes orthologues of the stem 
cell regulated exons in zebrafish in order to find a good model gene to 
investigate alternative splicing mechanisms. 
   To investigate an alternative splicing event of ITGA6 paralogues and 
orthologues in zebrafish development  
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2.3 Materials and Methods  
2.3.1 Zebrafish dissection method:  
 
Dissection was performed on zebrafish embryos (24 and 48 hours post-fertilisation). 
Firstly embryos were put in PBS in order to maintain osmotic balance. After that the 
embryonic shield was cut by using sharpened forceps. Next, needles (26 gauge) were 
used to dissect the zebrafish. Finally heads and tails were collected by pipet and placed 
in a new Eppendorf tube containing Trizol (Figure 2.2) 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2: The steps of head and tail dissection from zebrafish embryos after 24 
hours. A Zebrafish embryo is covered by shield. B. The embryonic shield is pulled 
away. C  Zebrafish embryo at 24 hours. D. head and tail after dissection.  Photos 
taken from a previous dissection by Alicia Madgwick. 
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2.3.2 RNA extraction:  
 
200 µl of Trizol (Life technology) was added to tissue or cells in an Eppendorf and 
vortexed, then incubated at room temperature for 5 minutes and 40µl chloroform was 
added. Samples were vortexed again and incubated at room temperature for 5 
minutes. Samples were then centrifuged at 13,000rpm for 15 mins at 4C. The 
supernatant was carefully transferred (approximately 100 µl, avoiding the interface) to 
a new Eppendorf tube and 100µl isopropanol was added. Next, samples were briefly 
vortexed and incubated at room temperature for 5 min. Samples were vortexed again 
and centrifuged at 13,000rpm for 15 min at 4⁰C. After that, the aqueous phase was 
removed. The pellet was washed by adding 100µl of 70% ethanol and spun for 5 min at 
4⁰C. The liquid was removed and the pellet was allowed to air dry. Finally, 10 or 20 µl 
of Diethylpyrocabonate(DEPC)-treated dH20 was added to re-suspend the pellet and 
the concentration was quantified on a ‘Nanodrop’ spectrophotometer.  
2.3.4 Geneious program 
 
‘Geneious’ is a bioinformatics program with multiple functions. It was used to align 
different paralogues and homologues of ITGA6. It was also used to interpret DNA 
sequencing results. Geneious links to NCBI and BLAST database, which it uses for 
downloading a nucleotide or protein sequence into the database used here. 
 
2.3.5 Primer design  
 
For the subsequent PCR, primers were designed to amplify both alternative splice 
forms simultaneously so the ratio of the two could be calculated. The primers were 
thus designed in adjacent exons to the alternative exon so that they would only 
amplify mRNA, because pre-mRNA and contaminating genomic DNA both contain 
introns which are sufficiently long that their products are at a disadvantage and 
therefore will not compete significantly. Primers were designed to target the same 
alternative splicing events in the orthologous genes in zebra fish by using the Primer3 
program. Homologous exon sequences, on which to design the primers, were provided 
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by Dr. Philippe Fort (Montpellier). Primers were synthesised by Integrated DNA 
Technology (IDT) (Table 2.1 ). The 10 genes in zebrafish were homologues of the 10 
alternative splice variants shown to shift between stem cell and fibroblasts (Venables 
et al., 2013b) (Table 2.2 ) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.3.6 PCR 
    Table 2.2: ITGA6 paralogues and orthologue zebrafish primers 
Primer  Sequence  
zITGA3A  (F) TATGCTGGGCGTGATTGTTA 
zITGA3A  (B) GCCTAAGCGAGACAGTTTGC 
zITGA3B  (F) AGTTCCCCTCTGGATCATC 
zITGA3B  (B) CCCAGAGTTTCTTGCTGAGG 
zITGA6A  (F) TGGCTGTGTTAGCTGGAATC 
zITGA6A  (B) ACGTGGTCATCCACTGCTTC 
zITGA6B  (F) TTGCTGGGCTTACTGGTCTT 
zITGA6B  (B) CATTTCGTCTTTGCCTGACA 
zITGA7    (F) CGCTGCTCGTGTGTTTACTG 
zITGA7    (B) ATGAGTGTGTCGTCCAGCAG 
    
 
 
 
           Table 2.1: primers for orthologues of the 10 genes 
Primer Sequence  
MARK2   (F) ACCAGCACAAATCGAAGCAG 
MARK2   (B) AGGCAACAGGGACACGCT 
PPIP5K1  (F) CCGAATCTTCAGGACTACGC 
PPIP5K1  (B) GGGCATTATGCAGTGTTTCC 
FMNL3   (F) GCGGGAATTTCTGAATGATG 
FMNL3   (B) CACTAGGCGGGAGTTCTTCA 
FNIP1      (F) GCAGCAGTATTTGTGGGAGTC 
FNIP1      (B) TCCAGGCATGTCCATTGG 
KIF13A    (F) TGCCACTTATGGTTGAAGCCA 
KIF13A    (B) TGCATCTGACCACCTCTCCCTT 
PALM      (F) ACAAGCGAGTCTCCAACACG 
PALM      (B) GTCCGCTTTGTGGATGAGTT 
ATP2A1   (F) AGTTCGTTGCTCGGAACTACC 
ATP2A1   (B) GCCTGAAGATGTGTCACTATCG 
ITGA6      (F) ATCATCCTAGTGGCTATTCTCGC 
ITGA6      (B) ACTGTCATCGTACCTAGAGCGT 
PLOD2     (F) TTTGTTCGTGATAAACTGGATCC 
PLOD2     (B) GCAGTGGATAATAGCCTTCCAA 
CLSTN1   (F) CACAGAGAACGACAACACCG 
CLSTN1   (B) CGAATGACTCCCTCACCAGT 
CTTN       (F) ACAGACAAGACAAATGTGCCC 
CTTN       (B) TATCCATCCGATCCTTCTGC 
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Standard ‘endpoint’ PCR was performed with Invitrogen ‘Platinum Taq’ hot start PCR 
enzyme following the manufacturer’s instructions. Table 2.3 shows the 5X stock buffer 
made for all PCR master mixes table 2.4. The final PCR mix used to amplify alternative 
splicing products of cDNA is shown in table 2.5.  
      
         Table 2.3 : 5xbuffer stock (1ml) 
Components volume 
Platinum Taq 10X buffer 500 µl 
25mM dNTPs 40 µl 
50mM MgCl2 150 µl 
water 310 µl 
  
        Table 2.4: PCR component for 50µlx reaction  
Component  Volume 
5Xbuffer  10µl 
H2O 34.75µl 
Primers (50µM mixed forward and reverse primers)  1µl 
cDNA  (12.5ng/ul) 4µl 
Platinum Taq polymerase  0.25µl 
 
Table 2.5: PCR procedure 
PCR steps Temperature C Time  
 
Cycle  
Initial enzyme activation and DNA denaturing step 95 2 min 1 
Denaturing 94 30 sec 35 
Annealing 55 30 sec 35 
Elongation 72 30 sec 35 
Final extension 72 2min  
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2.3.7 Gel electrophoresis  
 
PCR products (12 l) were run on 1.5% agarose for product size estimated. Gel 
preparation was done following the protocol in table 2.6 , 2.7&2.8.    
   
 
 
Table 2.6: Electrophoresis gel protocol (1.5%) 
 Component Volume 
  Water 126ml 
  10X TBE 14ml 
  Agarose 2.1g 
  Ethidium bromide 0.5 μg/ml  11μl 
 
Table 2.7: 10X TBE (1litre) components 
Component               Volume 
Tris base 108g 
 Boric acid 55g 
 0.5M EDTA (at pH8) 40ml 
 Water 960ml 
 
Table 2.8: 0.5M EDTA (at pH8) 
Component Volume 
EDTA 74.49g 
 Water 400ml 
 NaOH was added until the solution reached pH8 
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2.4 Results: 
2.4.1 Alternative splicing in 10 genes in zebrafish head and tail. 
 
Before beginning the study, 10 genes, including ITGA6,PLOD2, CLSTN1, ATP2A1, PALM, 
KIF13A, FMNL3, PPIP5K1, MARK2 and FNIP1, which showed an alternative splicing 
event in stem cell differentiation, were chosen for analysis in zebrafish. Due to the 
importance of alternative splicing in stem cells and the relevance of stem cell cultures 
to model differentiation and development, I began my PhD project with the aim of 
further investigation of these genes in order to identify a good paradigm gene which 
regulated by different proteins and has impact function in cells in order to study 
alternative splicing mechanism. To first profile the extent of alternative splicing events, 
a panel of 10 genes with alternative splicing events across zebrafish tissue 
development including a 24 hours post-fertilization were studied. 
To investigate potential alternative splicing events of orthologues in these 10 genes 
zebrafish embryogenesis, I collected zebrafish heads and tails at 24 hours post-
fertilization (the full experiment details are detailed in the methods and materials 
section). RT-PCR with specific primers designed across each alternative splicing events 
was employed to evaluate the ratio of inclusion and exclusion exons.  PPIP5K1, 
CLSTN1, PALM, FNIP and PLOD2 express only the short form (exclusion exon) in both 
head and tails of zebrafish.   ATP2A1 expresses two isoforms (inclusion and exclusion) 
in only tail, whereas FMNL3 express two forms (inclusion and exclusion) in only head of 
zebrafish. MARK2 was not expressed at all in head and tail of zebrafish. The  
interestingly, KIF13A and ITGA6, out of the 10 exons tested, showed specific 
alternative splicing between the heads and tails. KIF13A and ITGA6 showed both mRNA 
isoforms (exon inclusion and exclusion) in tails; however, only the short form 
(exclusion exon) was visible in heads (Figure 2.3).  
Because KIF13A and ITGA6 were the only genes that showed specific alternative 
splicing between heads and tails at 24 hours post-fertilization, it was decided to look at 
these ASEs in different stages of zebrafish development to find exactly when splicing 
patterns shifted. Samples were taken from the zebrafish at different stages in the first 
two days post-fertilization (2, 4, 5, 11, 15, 28 and 48 hours). Here, Interestingly, ITGA6 
mRNA isoforms gradually shifted towards increasing inclusion (long form), from two 
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hours to 15 hours, and towards full reversion to exon skipping at 48 hours. KIF13 
gradually shifted towards increasing inclusion (long form) from 15 hours to 48 hours 
(Figure 2.4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3: Developmentally regulated alternative splicing in zebrafish. Agarose 
gel illustrating changes in ASEs in zebrafish embryogenesis:  Alternative splicing 
in 10 genes in zebrafish head and tail (see materials and methods) 24 hours post-
fertilization. KIF13A and ITGA6, in the third column, out of 10 genes show 
alternative splicing events between head and tail. The lower band represents the 
short form (exon exclusion) and upper form represents the long form (exon 
inclusion). 
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Figure 2.4:  Developmentally regulated alternative splicing in zebrafish. Agarose 
gel illustrating changes of ASEs in zebrafish embryogenesis.  Agarose gel showing 
the two ASEs that shift in their inclusion ratios during embryogenic development 
from 2 to 48 hours. 
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2.4.2 Investigation of ITGA6 alternative splicing in vertebrates   
 
Since ITGA6 splicing shifts most strongly in zebrafish embryogenesis out of the 
previously identified conserved stem cell splicing events (Venables et al., 2013b) we 
decided to concentrate our efforts on investigation of this gene. Therefore Dr Philippe 
Fort (CRBM Montpellier, France) launched a deeper investigation into the evolution of 
this alternative splice in the ITGA6 C-terminus and its paralogues in different species. 
By mining EST and genomic sequences ITGA3, ITGA6 and ITGA7 each show two 
different forms due to alternative splicing in all vertebrate species. Furthermore, in 
zebrafish, there are two paralogous ITGA6 genes and two paralogues of the ITGA3 
gene, so there is homologous alternative splicing of 5 genes in zebrafish (Figure 2.5). 
By alignment of the sequence of all C-termini in different species, Dr. Fort showed that 
the two alternative C-termini produced by alternative splicing (a and b) cluster 
together for ITGA3, ITGA6 and ITGA7. The similarity in amino acid of the ‘a’ forms of 
ITGA6 and ITGA3 are extremely strong as are the similarity between the ‘b’ forms of 
these genes across the three different genes and across different vertebrate species. 
The a and b forms of ITGA7 also cluster with the respective a and b forms of the other 
genes although with slightly less similarity (Figure 2.6). Overall these amazing results 
provide the unprecedented conclusion that alternative splice forms in C-termini of 
ITGA3, 6 and 7 are more fundamentally different (and likely more functionally 
important) than any distinction between the 3 genes (or 5 genes in zebrafish) 
themselves. This observation led us to investigate the function and regulation of this 
conserved alternative splice choice in ITGA6. 
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Figure 2.5: Paralogues and orthologous of ITGA6. Genetic tree for ITGA3, ITGA6 
and ITGA7 is shown for both the ‘a’ and ‘b’ alternatively spliced isoform in different 
species.  
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2.4.3 Investigation of paralogues and orthologues of ITGA6 in Zebrafish Head 
and Tail after Post- Fertilization.     
 
The previous bioinformatics and RT-PCR for ITGA6 revealed that there are 5 
homologues and paralogues of ITGA6 with regulated splicing in their downstream 
regions. To investigate alternative splice events, the regulated splicing of these ITGA6 
homologues and paralogues were tested in head and tail of 24 hours post-fertilization 
zebrafish by RT-PCR. 2 genes (ITGA6A and ITGA6B) showed alternative splicing 
patterns between head and tail. The other homologues, ITGA3A and ITGA3B and 
ITGA7, appear to be expressed at very low levels such that they were barely detected 
by RT-PCR.  ITGA6A showed long form (exon inclusion) in tail, whereas the short form 
(exon exclusion) appears in both head and tails. ITG6B also expresses the long form in 
tail while the short form is present in both head and tail (Figure 2.7). 
Although ITGA6A and ITGA6B showed alternative splicing event differences between 
head and tail, it was important to define them in zebrafish development, as each stage 
might show a dynamic pattern over this time frame. The original PCR I had done on 
zebrafish development was just for the ITGA6A gene. Therefore I re-performed the 
analysis for both ITGA6A and ITGA6B genes individually. The cDNA from different 
stages in embryogenesis was investigated by using RT-PCR and agarose gel 
electrophoresis. For ITGA6A, the smaller band (292bp), which represents the short 
form (exon exclusion), is visible in all development stages from 4.5 up to 48 hours, 
whereas the upper long form (exon inclusion) appears gradually from 11 hours up to 
15 hours, before starting to disappear again from 15  to 48 hours (Figure 2.8 A).  On 
the other hand the ITGA6B gene is also regulated, but in a completely different way. 
For ITGA6B, the major lower band (137bp), representing the short form (exon 
exclusion), is present in all stages, while the long form (186bp) appeared only from 24 
hours post fertilization (Figure 2.8B) 
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Figure 2.7: Alternative splicing of 5 zebrafish paralogues of ITGA6 in head and tail, 
24 hours post-fertilization. Upper band represents long form (exon inclusion) and 
lower band represents short form (exon exclusion). ITGA3A, ITG3B and ITGA7 did 
not produce any RT-PCR product 
                                                          
 
Figure 2.8 : Alternative splicing for ITGA6A and ITGA6B in development stages 
from 2 hours to 48 hours post-fertilization in zebrafish. A) Agarose gel 
illustrating alternative splicing for ITGA6A and ITGA6B in zebrafish development. 
The long form (292bp) clearly appears at 15 hours whereas the short form 
(195bp) is visible at all stages from 11 to 48 hours in ITGA6A.  In ITGA6B, the 
long form (186bp) is visible just at 28 and 48 hours, whereas the short form 
(137bp) clearly shows in all stages. B) The chart shows different of alternative 
splicing event between ITGA6A and ITGA6B during zebrafish development 
stages.  
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2.5 Discussion 
 
2.5.1 Validation of a novel alternative splicing event from Zebrafish 
development:  
 
Interest in alternative splicing is gaining momentum and now widely considered as an 
important mechanism for controlling gene expression. During cell differentiation, it is 
known that gene expression can be changed at different levels including alternative 
splicing  (Han et al., 2013, Venables et al., 2013b). The purpose of this study was to 
investigate alternative splicing during cell differentiation more deeply than has been 
done before. As conservation of regulated alternative splicing events has been 
reported across evolution (especially across vertebrate radiation) (Merkin et al., 2012), 
there is clearly a potential to investigate vertebrate alternative splicing by using the 
tractable genetics of the zebrafish model organism.  
The Zebrafish model has several advantages, which allow for an understanding of the 
functions of alternative splicing in development. One advantage of using the Zebrafish 
embryonic model is that development occurs rapidly until 72 hours post-fertilisation 
and all major organs appear after 36 hours and hatching occurs from 12 -36 hours. 
Between 2 hours post fertilization (hpf) and 48hpf, zebrafish embryos develop rapidly 
through many stages (Figure 2.9). In the first 2 hours post fertilisation, cells multiply to 
reach the 64-cell stage. The epiblast forms from around 5hpf. Between 10-24hpf the 
segmentation period occurs and organogenesis commences and somite development 
takes place after 24hpf until 48hpf (Kimmel et al., 1995).  
 We hypothesised that alternative splicing may play a significant role in embryonic 
development in zebra fish. Therefore I investigated the orthologues of 10 genes in 
zebrafish development, for which alternative splicing events have been documented in 
stem cell differentiation (Venables, et al., 2013). ITGA6 and KIF13 had specific 
alternative splicing changes between head and tail after 24 hours of development. 
Exon exclusion was seen just in in both head and tail; however exon inclusion was just 
seen in tail which might give a clue that both isoforms of mRNA have an important role 
in embryonic devolvement of zebrafish tail (which is mostly composed of muscle).  
Since ITGA6 and KIF13 had specific alternative splicing differences between head and 
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tail, I went on to observe their splicing patterns during a time course of zebra fish 
embryonic development. Interestingly, the ITGA6 long form peaked at 15hps, which 
may suggest that the longer form plays a significant role in forming the epiblast, and 
more generally has an impact on cellular function during embryonic development of 
vertebrates.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure19: Stages of embryonic development of the zebrafish. Image adopted  from (Kimmel, 
Ballard, Kimmel, Ullmann, & Schilling, 1995) 
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2.5.2  ITGA6 alternative splicing pattern in zebrafish  
 
ITGA6 belongs to the integrin family, which are dimeric cell-surface proteins composed 
of an alpha chain and a beta chain (Sastry and Horwitz, 1993). It has been reported 
that there are three paralogues in mammals for ITGA6, including ITGA3 and ITGA7, 
which have a close evolutionary relationship (Sastry & Horwitz, 1993). Interestingly, we 
found that there are five close paralogues of ITGA6 in zebrafish, compared with the 
three close genes in ITGA3, ITGA6 and ITGA7 in mammals. This is caused by the ancient 
duplication of the ITGA6 and ITGA3 genes. Amazingly, two C-terminal isoforms of all 
these proteins are conserved even in zebrafish. The two C-terminal isoforms including , 
the ‘a’ and ‘b’ forms are more closely related between paralogues and orthologues 
than the orthologues and paralogues themselves. In other words, the The two C-
terminal isoforms ( a and b ) has more conserved between paralogues and orthologues 
, whereas the two C-terminal isoforms ( a and b ) has less conserved between the 
paralogues genes or orthologues. 
 
Alternative splicing  of ITGA6 has been reported during stem cell differentiation 
(Venables et al., 2013). Alternative splicing ITGA3 and ITGA7 have been reported in 
mouse embryogenesis. In this study, the five paralogues of ITGA6 in the head and tail 
24 hours post-fertilization and in the embryogenesis developmental stages of zebrafish 
were observed. ITGA6A and ITGA6B had similar specific alternative splicing, with the 
long form appearing only in tail.  
 
Do both ITGA6 A and B have the same alternative splicing events and functions? Some 
studies have reported that ITGA6 A and B have the same function in mouse 
embryogenesis (Gimond et al., 1998). However, they showed different timings of these 
splicing events during embryogenesis, which suggested that splicing control of both 
ITGA6 genes also might play a major role during zebrafish embryonic development. 
There is some evidence showing that ITGA6 isoforms A and B are involved in different 
functions of cancer stem cells (Gimond et al., 1998). 
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ITGA3 and ITGA6 show alternative splicing patterns in mouse embryos during 
development. Interestingly, I found that ITGA3 and ITGA7 have low expression in 
zebrafish embryogenesis. It is tempting to speculate that the major functional alpha 
integrins in embryogenesis in zebrafish are provided by ITGA6A, ITGA6B and their four 
respective alternatively spliced isoforms (ITGA6Aa, ITGA6Ab, ITGA6Ba and ITGA6Bb). 
However, in other organisms, the important functions might be provided by a different 
combination of the ITGA3, ITGA6 and ITGA7 genes, albeit with essential functions for 
the a and b isoforms. 
 
 
 
 
2.6 Chapter Summary 
 
In this chapter, the different pattern  splicing for ITGA6,  PLOD2, CLSTN1, ATP2A1, 
PALM , KIF13A, FMNL3, PPIP5K1, MARK2 and FNIP1 have been shown these an 
alternative splicing event in stem cell differentiation in zebrafish. ITGA6 and KIF13A 
were the only genes that had different patterns of splicing between head and in tail 
after 48 hours post-fertilization in zebrafish. It was found that ITGA6 has a different 
pattern of splicing during the development stage of the zebrafish.  
We identified thatITGA6 has five paralogs in zebrafish. These have   interestingly 
conserved two C-terminal isoforms. Only ITGA6 a and b of the five paralogues has a 
different expression pattern between head and tail after 24 hours of development. 
They also showed different timings of these splicing events during embryogenesis.  
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Chapter 3: Identification of PTBP as a novel regulator of 
the ITGA6 splicing switch 
 
3.1 Introduction 
 
ITGA6 plays an important role in many aspects of a cell’s biology, including cell 
signalling and interactions with the cell matrix. It has been reported that ITGA6 was 
one of 15 ASEs that shift from one isoform to another during stem cell differentiation 
(Venables et al., 2013b). Both isoforms (ITGA6A and ITGA6B) are involved in regulating 
tumorigenesis, including proliferation and metastasis (Goel et al., 2014). It has been 
suggested that the two splicing variants of α6 integrin have a specific function in 
tumorigenesis (Goel et al., 2014). These studies raise the importance of knowing how 
alterative splicing of ITGA6 is regulated. In this chapter, the aim was to investigate how 
ITGA6 splicing is regulated.  
 
The alternative exon 25 of ITGA6 has been reported to be controlled by two separate 
splicing factors, Muscleblind-like (MBNL1) and Forkhead transcription factors 
(RBFOX2), which also involved in cellular differentiation (Venables et al., 2013b). Both 
MBNL1 and RBFOX2 proteins can act as repressors or activators of alternative exons 
based on binding site location. MBNL1 and RBFOX2 proteins bind downstream of the 
exon to enhance inclusion and upstream to inhibit inclusion. Venables et al. (2013) 
showed that MBNL1 and RBFOX2 regulated the enhanced splicing inclusion of the 
ITGA6 exon during stem cell differentiation.   
 
(Goel et al., 2014) showed that there is a third regulation factor, epithelial splicing 
regulator protein (ESRP1), which also regulates ITGA6 alternative exon.   ESRP1 is part 
of a positive feedback loop downstream of vascular endothelial growth factor VEGF. It 
has been reported that ESRP binds downstream of the ITGA6 alternative exon to act as 
an activator in breast cancer cell lines (Warzecha et al., 2010b). Thus there are three 
splicing factors which enhance the ITGA6 alternative exon: MBNL1, RBFOX2 and 
ESRP1. 
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Although it has been reported that the ITGA6 alternative exon is regulated, or 
activated, by MBNL, RBFOX and ESRPs, other important splicing factors are poly 
pyrimidine tract-binding proteins PTBP1 and PTBP2, which are expressed in all cells 
except mature neurons.  PTBP1 and 2 are part of a family of three splicing factors that 
have largely redundant functions and which auto-regulate each other’s expression. The 
homologues of PTBP form one of the most significant RBP families that have been 
studied in mammals (Valcarcel and Gebauer, 1997b). The prototypical member PTBP, 
or HnRNPI, generally functions as a splicing repressors. PTBP also functions in a 
number of diverse cellular processes, including polyadenylation, mRNA stability, mRNA 
localisation and translation (Sawicka et al., 2008a). PTBP binds to splicing silencers at 
pyrimidine-rich motifs, such as UCUU or CUCUCU in the RNA, to mediate splicing 
repression in a long list of alternatively spliced pre-mRNAs (Noiret et al., 2012b). In this 
chapter, I aimed to investigate whether PTBP regulates alternative splicing of ITGA6.    
 
3.2 Aims 
 
- To investigate splicing pattern of ITGA6 in different cancer cell lines. 
- To confirm that RBFOX, MBNL1, ESRPs activate ITGA6 alternative exon in 
cancer cell lines.  
- To test if PTBP acts as a potential novel regulator for the ITGA6 alternative 
exon, and investigate whether PTBP acts as an activator or inhibitor.   
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3.3 Materials and Methods 
3.3.1 Quantitative real time PCR (qPCR) 
 
Quantitative real time PCR was used to determine gene expression using a SYBR green 
PCR master mix kit (applied Biosystems) and an applied for Biosystems fast real time 
PCR machine. In this chapter, qPCR was used to determine gene expression of the 
splicing regulation factors inclusion PTBPs and MBNL1 in cancer cell lines. RNA samples 
were collected from HeLa and MCF7 cells 72 hours after of siRNA transfection. After 
RNA extraction, Maxima Reverse Transcriptase First strand cDNA synthesis kit (Thermo 
Scientific) including enzyme mix and 5x buffer mix was used in order to make cDNA. 
RT-PCR was performed following the manufacturer’s instructions (Table 3.1 &3.2). 
cDNA was diluted in 1/20 using RNase-free water (Ambion) and used for PCR. After 
that the 9 ul of PCR master mix was added per well to a 96 well qPCR plate containing 
1ul diluted cDNA per well. qPCRs were performed using a minimum of 3 replicate 
samples per sample. A control was used for each master mix which had no template. 
The plate was loaded into the instrument and standard cycling conditions were 
performed (Table 3.3 &3.4). After that, gene expression was calculated using software 
(Applied Biosystems) which calculated ct value and CSDS using the average of three 
reference genes, GAPDH, Tubulin and Actin. All primers used for quantitative real-time 
PCR (qPCR) are provided in Table 3.5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
Table 3.1: components of reverse transcription 
components Volume 
RNA sample (variable volume) 3µg 
5x mix 4µl 
Enzyme mix 2µl 
water To complement RNA to 14 µl 
 
Table 3.2:  Temperature sequence of RT reaction 
steps Temperature (C) Time(min) 
annealing 25 10 
elongation 50 30 
Termination  85 5 
cold 4 ∞ 
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           Table 3.3: components of qPCR 
Components    Volume  
2X SYBR Green PCR Master Mix 5μl 
Forward primer (10μM) 1μl 
Reverse primer (10μM) 1μl 
RNase-free water 2μl 
Total  9μl 
 
           Table 3.4 : steps of qPCR  reaction  
Steps  Temperature (C) Time Cycles  
Heat activation  50 2min  
Initial denaturation   95 10 min  
Denaturation  95 15 second   
Annealing/elongation  60 1 min Cycling to step 3  45  
 
           Table 3.5: Primers designed to targeted regulatory proteins for qPCR 
Primers  Sequences  
PTBP1variable exon3 F  GCCTGACCAAGGACTACGG 
PTBP1 variable exon 3 Rev CCCCATTGCTGGAAAACA 
PTBP2variable exon3 F  GTGGCTCGGTTCTTGTGA 
PTBP2 variable exon 3 Rev TGCCTGAGAGTAGTTCGTCA 
RBFOX2 variable exon3 F  TCATCTATCCGTTTGGTTTAT 
RBFOX2 variable exon 3 Rev TGGCGTCAGGAGTTGTTGTC 
ESRP1 variable exon3 F  AGCACTACAGAGGCACAAACA 
ESRP1 variable exon 3 Rev TGGAGAGAAACTGGGCTACC 
ESRP2 variable exon3 F  GGGAGTTCGCCACAGATATTC 
ESRP2 variable exon 3 Rev AGCCATAAATGCTCTGTCCG 
MBNL1 variable exon F  GCTGTTAGTGTCACACCAATTCG 
MBNL1 variable exon Rev  AGGCGATTACTCGTCCATTTTC 
ACTB For (reference gene 1) CATCGAGCACGGCATCGTCA 
ACTB Rev (reference gene 1) TAGCACAGCCTGGATAGCAAC 
GAPDH For (reference gene 2) ATCATCCCTGCCTCTACTGG 
GAPDH Rev (reference gene 2) GTCAGGTCCACCACTGACAC 
α6A f CCACATATCACAAGGCTGAG 
α6A Rev CACTGTCATCGTACCTAGAG 
ITGA6  constitutive f CTGGGATCTTGATGCTTGCT 
ITGA6  constitutive Rev GCAGTTTGGGTACTGTGAAGC 
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3.3.2 Cell culture 
3.3.2.1 Cell lines  
 
In this chapter, three human cancer cell lines including:  MCF7 (catalogue number: 
ATCC-HTB-22), MDA-MB-231 (catalogue number: ATCC-HTB-26) and HeLa (catalogue 
number:  ATCC-CCL-2) were used. All this cell lines were purchased from the American 
type Culture collection (ATCC) and LGC stander, Europe 
 
3.3.2.2 MCF-7  
 
The human cell line MCF7 was originally established from pleural effusion of a 69 years 
old caucasian female patient with breast adenocarcinoma (Soule et al., 1973). MCF7 is 
a tumorigenic breast cancer cell line but less invasive than MDA-MB231 (below), early 
staged and ER and PR positive. 
 
3.3.2.3 MDA-MB231 
 
The human cell line MDA-MB231 was originally established from pleural effusion of a 
51 year old female patient with breast cancer adenocarcinoma (Cailleau et al., 1978). It 
is tumorigenic breast epithelia with invasive characteristics in early stage. ER and PR 
are negative in this cell line.  
 
3.3.2.4 Hela  
 
HeLa is a tumorigenic cervix epithelia cell line originally derived from a 31 years old 
black female patient with cervical cancer. This cell line is often used in splicing assays 
due to high efficiency observed for transfection.  
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3.3.2.5 Cell culture condition   
 
Cell culture was performed in a class 11 laminar flow microbiological safety cabinet. All 
cell line were grown in (25cm2 and 75cm2) flask in a 37°C incubator containing 5% CO2. 
DMEM (Dulbecco’s Modified Eagle’s Media) without phenol red (purchased from PAA) 
with 10% FBS and 1% penicillin streptomycin added (purchased from Sigma-Aldrich) 
was used as a culture medium for all cell lines including MDA-MB231, MCF-7 and HeLa.  
 
 
3.3.2.1 .6 Cell line maintenance  
 
Every 3 to 5 days on average, cells were passaged at roughly 70-80% confluency in 
flasks. To do passaging, growth on media (DMEM) was removed and the cells were 
washed with sterile 1x phosphate buffered saline (PBS) (Sigma-Aldrich). 2mM trypsin-
EDTA (Sigma-Aldrich) was added to the cell and incubated for 5 min at 37°C.  Growth media 
was added in order to stop the effect of trypsin. This was followed by centrifugation of the 
cells at 200xg for 5 min in order to collect detached cells. The supernatant was removed and 
the pellet was suspended in complete growth media and placed in new flask at a ratio 1:5 
(diluted cells to new culture media). 
 
3.3.2.1.7 Cryopreservation of cells  
 
To generate a continuous stock of cells, cells were routinely frozen at early passage 
number. After cells reached roughly a confluency of 70-80% in flasks, the cells were 
passaged and aliquots placed in cryoprotective media, which consists of 95% FBS with 
5% dimethl sulphoxide (DMSO) (Sigma- Aldrich). This was frozen and stored at -80°C. 
When required, frozen cells were thawed. Thawing was performed rapidly at 37°C in a 
water bath, and media removed by centrifugation at 200xg for 5 min. Cells were 
resuspended in complete growth media and plated in new tissue culture flasks. 
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3.3.2.1.8 Capillary gel electrophoresis (Qiaxcell) 
 
Capillary gel electrophoresis (Qiaxcell) is advanced fully automates sensitive system 
replaces traditional labor-intensive gel analysis of DNA and RNA using ready gel 
cartridges. It   was performed using 5 µl of RT-PCR samples diluted with 5 µl Qiaxcell 
dilution buffer (Qiagen). This was followed by loading samples in the multi-capillary 
electrophoresis system. Qiaxcell biocalculator software was used to determine the size 
and concentration of each PCR product.  
 
3.3.3 Calculation of percentage splicing inclusion (PSI %) 
 
In this chapter, the percentage of splicing inclusion was calculated using following 
formula figure 3.1  
 
 
 
3.3.4 Gel electrophoresis  
In this chapter, gel electrophoresis was used following the protocol described in 
chapter 2. 
 
3.3.5 Western immunoblotting  
 
Western immunoblotting was used to determine protein expression levels. PTBP1 and 
MBNL1 proteins were detected by western blotting using rabbit monoclonal PTBP1 
antibody (Abcam, ab63697) and rabbit polyclonal MBNL1 antibody (Abcam, ab45889).  
This was followed by secondary α-rabbit HRP (all antibodies 1:1000 dilution). Efficiency 
of loading and transfer were measured using actin immunoblotting and GAPDH.  In 
brief, after harvesting cells, cell pellets were lysed in 2X SDS loading buffer. This was 
followed by boiling at 100C for 5 min. Proteins were separated by 10 % SDS-PAGE, 
followed by transfer to Hybond-P membranes (GE). Membranes were blocked for one 
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hour in block solution (Tris Buffer Saline (TBST) 5% with non-fat dry milk). The 
membrane was washed three times for 5 minutes each in TBST and then probed with 
primary antibody overnight at 4C. Following this, membranes were washed three 
times for 5 minutes with TBST, and further probed with secondary antibody for one 
hour. Finally membranes were washed three times using TBST for 5 minutes. This was 
followed ECL detection using ECL western blotting detection reagent (Amersham). 
Excess ECL was then removed and filters were exposed on photographic film (Kodak).  
Films were developed in a Compact X4 developer (Xograph Imaging Systems). 
 
3.3.6 siRNA Transfection: 
Knockdown for the endogenous PTBP1, PTBP2, MBNL1, RBFOX2, ESRPS1 and ESRPS2 
was achieved by transfecting MCF-7 and HeLa cell lines with silencer selected pre-
designed siRNA (Integrated DNA Technologies (IDT)). SiRNA PTBP1 
(NM_031990)(hs.Ri.PTBP1.13.1) PTBP2 (hs.Ri.PTBP2.13.2) (NM_021190),  MBNL1 
(hs.Ri.MBNL1.13.2)(NM_021038), RBFOX2 (hs.Ri.RBFOX2.13.2) (NM_001082578), 
ESRP1 (hs.Ri.ESRP1.13.3) (NM_001122827) and ESRP2 (hs.Ri.ESRP2.13.2)( NM_024939)  
were transfected using Lipofectamine RNAiMAX™  reagent (Thermofisher). Control 
(untreated) cells were treated with transfection reagent only. Transfection was 
performed following the manufacturers instructions (Table 3.6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.6: Transfection protocol 
Transfection 
protocol 
Reaction mix 
Components volume Incubation 
time 
Mix 1 Opti-MEM® Medium 150μL 
 
5minutes 
Lipofectamine RNAiMAX reagent 9 μL 
Mix2 Opti-MEM® Medium 150 μL 5minutes 
siRNA (10 μM) 3 μL(30pmol 
Mix 3 Mix 1 160 μL 20 minutes 
Mix 2 155 μL 
Short Centrifugation 
Add 250 μL to each well in 6 well plate  and incubate at 37c  overnight 
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3.4 Results  
 
3.4.1 Splicing pattern of ITGA6 in different cell lines (HeLa, MCF7 and MDA-
MB231), stem cells and fibroblasts 
 
The alternative splicing of ITGA6 has been reported to have a different patterns 
between stem cells and fibroblasts (Venables et al., 2013). I sought to confirm this 
result, and to also test the splicing pattern in cancer cell lines. I performed RT-PCR 
using primers that were designed to match the constitutive exons that flanked the 
alternative exon of ITGA6. This assay used RNA from the HeLa, MCF7 and MDA-MB231  
cancer cell lines, as well as pre-existing cDNA from stem cells and fibroblasts as 
described by Venables et al. (2013). The details of the cancer cell lines, stem cells and 
fibroblasts are explained in the methodology chapter. The splicing pattern of the RNA 
expressed in each cell line was analysed using capillary gel electrophoresis. Two bands, 
one for exon inclusion and one for exon exclusion, could be detected by gel 
electrophoresis. The concentration between the isoforms was calculated using a multi-
capillary Qiaxcell gel electrophoresis system (Figure 3.1).  
 
The ITGA6 inclusion percentage was calculated and plotted on a barchart (Figure3. 1a). 
The pattern of splicing ITGA6 inclusion (long form) is predominant in fibroblast and 
breast cancer cell lines, including MCF7 and MDA-MB231. However, the exclusion 
pattern of the ITGA6 (short form) is the predominantly form in stem cells and the HeLa 
cancer cells line. Taken together, the breast cancer cell lines proved to be a good 
model to study how the alternative exon of ITGA6 can be activated as they roughly 
express the same levels of both isoforms of ITGA6, whereas the HeLa cancer cell line 
proved to be a good model to study how the ITGA6 alternative exon can be inhibited 
as they have less exon inclusion.  
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Figure 3-1: Investigation of ITGA6 alternative splicing control in different cancer 
cell lines. RT-PCR was performed using specific primers across the alternative 
exon of ITGA6 using RNA from different cancer cells. a) Graphs show the 
percentage of splicing inclusion (PSI%) in different cell lines , stem cells and 
fibroblasts. It illustrates changes in ASEs of ITGA6 in different cancer cell lines. 
Exclusion of the cassette exon is represented by the lower band (247bp), while the 
upper band represents exon inclusion (377bp). This experiment showed that exon 
25 is skipped in HeLa and stem cells, but included in MDA-MB231, MCF7 and 
fibroblasts 
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3.4.3 SiRNA knockdown of MBNL1, RBFOX2, and PTBPs in HeLa, MCF7 and 
MDA-MB231 cell lines  
 
The ITGA6 alternative exon is regulated by MBNL and RBFOX1 during stem cell 
differentiation (Venables et al., 2013). Since ITGA6 alternative splicing showed 
different patterns in different cancer cell lines, The knockdowns of the endogenous 
regulation factors, including MBNL1, RBFOX2, PTBPs and ESRPs, were tested to see if 
these   would affect the splicing patterns of ITGA6.  
  
To begin this study, siRNA targeted against these splicing factors were transfected into 
HeLa, MCF7 and MDA-MB231 cell lines. After 72 h, the cells were harvested, and a RT-
PCR was performed using specific primers located on the flanking constitutive exon 
followed by gel electrophoresis in order to analyse any alternative splicing changes 
(Figure 3.2). As expected, the ITGA6 splicing shifted towards the short form (exclusion 
of the alternative exon) upon knockdown of either MBNL1 or RBFOX2 in MCF7 and 
MDA-MB231 cells compared with the control (with no siRNA) (Figure 3.2a,b). 
However, the ITGA6 shifted from the long form (inclusion of the alternative exon) to 
the short form (exclusion of the exon) upon knockdown of RBFOX2 in HeLa cell line 
compared with the control (Figure 3.2c).. On other hand, the ITGA6 splicing shifted 
towards the long form (inclusion of the alternative exon) upon double knockdown of 
PTBP1 and PTBP2 in MDA-MB231, MCF7 and HeLa cells compared with the control.  
 
Overall, these results confirmed that the ITGA6 alternative spliced exon is enhanced by 
MBNL1 and RBFOX2. The results also showed for the first time that PTBP inhibits this 
exon. The ITGA6 alternative exon is thus under the control of three major splicing 
factors.  
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Figure 3-2. ITGA6 alternative splicing pattern after knocking down splicing 
regulation factors in the MDA-MB231, MCF7 and HeLa cell lines. Agarose gel 
shows ITGA6 splicing after knocking down PTBP1/2, MBNL1 and RBFOX2, 
respectively, in the MDA-MB-231 , MCF7 and HeLa cell lines. Exclusion of cassette 
exon appears as the lower band, while the upper band represents the inclusion.  
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3.4.3.1 Confirmation that splicing regulatory factors affect (activate) the 
alternative exon of ITGA6 in MCF7 cell lines 
 
The ITGA6 alternative exon has different splicing patterns in different cancer cell lines. 
Splicing regulatory factors, including  MBNL1, RBFOX2 and PTBPs have been shown to 
regulate the exon. The ITGA6 alternative exon has also been reported to be enhanced 
by ESRP1, which is part of the positive feedback loop downstream of VEGF. I decided 
to confirm this result using the MCF7 cell line due to the clearly of splicing events in 
pervious results. 
 
To begin this test, the siRNAs specific for MBNL1, RBFOX, PTBP and ESRP were 
transfected (in triplicate) into the MCF7 cell line. After 72 h, the cells were harvested 
and RNA purified. Reverse transcription of the RNA was then performed. The splicing 
pattern of the endogenous RNA was analysed using capillary gel electrophoresis. ITGA6 
showed two bands on the gel: a long form (inclusion of the exon) and a short form 
(exclusion of the exon). Ratios of the two bands were determined using a multi-
capillary Qiaxcell gel electrophoresis system in order to calculate the expression of 
both isoforms of ITGA6 splicing. The percentages of the alternative splicing pattern 
were calculated and plotted on a graph (Figure 3.3). The method of calculation is 
described in method section 3.3.3.  
 
As expected, the ITGA6 alternative exon had shifted from the long form (inclusion) to 
the short form (exclusion) upon knockdown of MBNL1 and RBFOX2 compared with the 
control (untreated or negative siRNA) cell. Double knockdown of ESRP1 and ESRPS2 did 
not show any change in the splicing pattern of ITGA6 compared with the control cells. 
This result confirms that the ITGA6 alternative exon is enhanced by MBNL1 and 
RBFOX2 but suggests ESRP proteins are not involved.  
 
In contrast, the ITGA6 alternative exon shifted from the short form (exclusion) to the 
long form (inclusion), with a double knockdown of PTBP1 and PTPB2 compared with 
the negative siRNA treated cell. This result confirms that ITGA6 alternative splicing is 
repressed by PTBPs.  
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Overall, these results confirmed that the ITGA6 alternative splicing exon is enhanced 
by MBNL and RBFOX, and inhibited by PTBPs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: The percentage splicing inclusion (PSI) of ITGA6 after knockdown of 
splicing regulation factors in the MCF7 cell line. Graphs show the percentage of 
splicing inclusion of the ITGA6 alternative exon which was compared between 
controls (without siRNA) (orange) and cells with knockdown of splicing regulation 
factors (PTBP, MBNL1, RBFOX2 and ESRP) (green). Data is represented as the 
mean of three biological replicates in each case. Statistical significance was 
calculated using an independent two-sample t-test, where *p<0.05, **p<0.01, 
***p<0.0001. Capillary gel electrophoresis image shows ITGA6 alternative 
splicing after knocking down regulatory factors in the MCF7 cell line.  Exclusion 
of the cassette exon appears in the lower band (246bp), while the upper band 
represents the exon inclusion (377).  
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3.4.3.1.1 Monitoring   MBNL knockdown in MCF7 cell lines 
 
As previously described result (3.4.3.1), ITGA6 splicing is activated by MBNL1 and 
RBFOX2 in the MCF7 cell lines. Because the knockdown of MBNL1 in MDA-MB231, 
MCF7 and HeLa cancer cell lines showed a clear shift from the long form to the short 
form compared with knockdown of RBFOX2, studied was focused on MBNL1 as a 
strong repressor factor. While the knockdown of MBNL1 was shown to enhance 
splicing the ITGA6 alternative exon via quantitative RT-PCR, it was important to 
confirm the efficiency of the knockdown of this protein.  
 
The siRNA specific to MBNL1 was transfected into the MCF7 cell line, and levels of this 
protein analysed via Western immunoblotting using a rabbit polyclonal antibody 
against MBNL and a rabbit monoclonal antibody against GAPDH as a control. 72 h after 
of transfection, efficient depletion of MBNL1 was observed in the transfected cells and 
compared with the negative control siRNA transfected cells (Figure 3.4A).  
 
Although the MBNL knockdown efficiency was confirmed by Western immunoblotting, 
this was also confirmed by qPCR as well. MBNL1 siRNAs were transfected into MCF7 
cells. After 72 hours, cells were harvested and cDNA was made from each cell. Using 
specific primers for MBNL1 (see Section 3.3.1), qPCR was performed to determine the 
MBNL expression. After the fold change was calculated (refer to method Section 3.3.3), 
the efficiency of MBNL depletion had significantly changed compared with the 
untreated cells (Figure 3.4B).  
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Figure 3.4 : Knockdown of MBNL1 in MCF7 cell  tested by western blotting 
and real time PCR. A) Depletion of endogenous MBNL1 was confirmed  in 
trplicate in MCF7 cells by Western blot. Expression of GAPDH was monitored 
as a loading control. B) qPCR detected the knockdown of MBNL1  in MCF7 cell 
line (represented in red) compared with the control (untreated cell) 
represented in blue. Data for the three biological replicates  and statistical 
significance was calculated using an independent two-sample t-test, where 
*p<0.05, **p<0.01, ***p<0.0001 . 
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3.4.3.2 Investigating the regulatory factors that inhibit the alternative exon 
of ITGA6 in the HeLa cell line  
 
Previous experiments in different cell lines identified that the splicing regulatory 
factors, MBNL, RBFOX and ESRPs, activated the alternative exon of ITGA6, and showed 
that PTBP acted as an inhibitor for the exon (refer to Section 3.4.3). The PTBP1 and 
PTBP2 double knockdown showed significant changes in the splicing pattern of ITGA6 
which inhibit alternative exon (more inclusion exon) in the MCF7 cell line (Figure 3. 3). 
However, it was important to test what happened in other cell lines that might have a 
different pattern of splicing control.    
 
I investigated the splicing pattern of ITGA6 using the HeLa cancer cell line, which had 
more exclusion for the alternative exon of ITGA6. siRNAs specific for MBNL1, RBFOX, 
PTBP (PTBP1&PTBP2), ESRP (ESRP1&ESRP2) were transfected in triplicate to the HeLa 
cell line. After 72 h, the cells were harvested and RNA was reverse transcribed. The 
splicing pattern of the endogenous RNA was analysed using capillary gel 
electrophoresis and the concentration for each form (long form and short form) was 
calculated using a multi-capillary QIAxcel gel electrophoresis system. The percentages 
of the alternative splicing pattern were calculated and plotted on a barchart.  
 
As expected, the ITGA6 alternative exon shifted from the long form (inclusion of the 
exon) to the short form (exclusion of the exon) upon the double knockdown of PTBP1 
and PTBP2 compared with untreated cells. In other words, the double knockdown of 
PTBP1 and PTBP2 resulted in a significant decrease in percent splicing in (PSI) of the 
ITGA6 exon from 68% to 41%. This result confirmed that PTBP (PTBP1 and PTBP2) act 
as repressors of the ITGA6 alternative exon (Figure3.5).  
 
The knockdown of MBNL1 resulted in a significant decrease in PSI from 68% to 82% in 
the ITGA6 exon as it shifted from the long form to the short form. However, the 
knockdown of RBFOX2 and ESRPs (ESRPs1 and ESRPS2 together) did not show an effect 
on the ITGA6 alternative exon compared with untreated cells. This result confirmed 
that the ITGA6 alternative exon was activated mainly by MBNL1.  
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Figure 3.5: The percentage splicing inclusion (PSI) of ITGA6 with knockdown of 
the splicing regulatory factors in the HeLa cells.  Graphs show the percentage of 
splicing inclusion of ITGA6 alternative exon compared between controls (without 
siRNA) with GFP (beige) and knockdown of regulation factors (PTBPs, MBNL1, 
RBFOS2 and ESRPs) green. Data represents the mean of three biological 
replicated in each case. Statistical significance was calculated using an 
independent two-sample t-test, where *p<0.05, **p<0.01, ***p<0.0001. Capillary 
gel electrophoresis image shows ITGA6 alternative splicing after knocking down 
splicing regulation factors in the HeLa cell line.  Exclusion of cassette exon 
appears in the lower band (246bp), while the upper band represents exon 
inclusion (377).  
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3.4.3.2.1 Monitoring PTBP knockdown in HeLa cell lines 
 
 
It is important to confirm the previous experiment (section 3.4.3.2) that indicated that 
the depletion of PTBP1 and PTBP2 repressed the ITGA6 alternative exon in cancer cell 
lines. siRNAs for PTBP1 were transfected into the HeLa cell line and PTBP1 analyzed 
using Western immunoblotting with a rabbit polyclonal antibody against PTBP1 and a 
rabbit monoclonal antibody against actin as a control. The expression of PTBP1 protein 
was detected on the Western immunoblot, and corresponded to the expected size of 
57 kDa for the full length of PTBP1 in the control (untreated cells). However, this band 
was significantly reduced after knockdown of PTBP1, which indicated that this band 
was specific for PTBP1 compared with the control (Figure 3.6a).  
 
Although the PTBPs knockdown efficiency was confirmed by Western immunoblotting, 
I wanted to confirm this result by doing qPCR. The PTBP1 and PTBP2 double siRNAs 
were transfected to the HeLa cell line. After 72 h, the cells were harvested and cDNA 
was made from each cell. Using specific primers for PTBP1, qPCR was performed to 
determine PTBP1 expression. The levels of PTBP1 significantly changed compared with 
the untreated cells after depletion (Figure 3.6b).  
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Figure 3.6: Knockdown of PTBP1 in Hela cell line  confirmed by  western blotting 
and real time PCR. A) Depletion of endogenous PTBP1 was confirmed  in triplicate 
in Hela cells by Western blot. Expression of GAPDH was monitored as a loading 
control. B) qPCR detected the expression of kncodown of PTBP1 in Hela cell line 
(shown in red) compared with the control (untreated cell) in blue. Data for the 
mean three biological replicates  and statistical significance was calculated using 
an independent two-sample t-test, where *p<0.05, **p<0.01, ***p<0.0001 . 
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3.4.2 Measurement of the relative levels of factors that regulate ITGA6 
alternative splicing 
 
I have demonstrated the ITGA6 alternative splicing pattern in cancer cell lines, stem 
cells and fibroblasts and also shown that an alternative exon of ITGA6 was activated by 
RBFOX2, MBNL1 and ESRP and inhibited by PTBPs in the cancer cell line. Since these 
regulatory factors have significant implications for the alternative splicing pattern, it 
was important to investigate the level of protein regulatory factors, including PTBP, 
RBFOX2, MBNL1 and ESRP, in the different cell lines.     
 
I analysed the expression of splicing regulation factors (the PTBP, RBFOX2, MBNL1 and 
ESRP isoforms) in different cell lines, including MCF7, MDA-MB231 and HeLa. I also 
used pre-existing cDNA for the stem cells and fibroblast, as demonstrated by Venables 
et al. (2013), and performed real-time quantitative PCR (qPCR) using the specific 
primers for the regulation factors (see primers, table 3.5, in the Methods section). 
To determine the expression of regulation factors that control ITGA6 alternative exon 
in different cell lines, I compared expression levels in cell types that have variant ITGA6 
isoform expression. MCF7 breast cancer cell lines were previously shown to have 
roughly the same level of expression for both the ITGA6 isoforms (inclusion and 
exclusion for alternative exon) (see Section 3.4.1). I compared MCF7 cell line with 
MDA-MB231 and HeLa cell lines as well as fibroblast and stem cells for the expression 
of the splicing factors PTB, RBFOX2, MBNL1 and ESRP.  
 
After calculating the fold change, the expression of PTBP1 was found to be highest in 
the HeLa cell lines, whereas the expression of PTBP2 was extremely high in the HeLa 
cell lines compared with the other cell lines. The expression of MBNL1 had roughly the 
same range of expression level in the different cancer cell lines, but was expressed at 
an extremely low levels in stem cells. RBFOX2 was expressed at a high level in MCF7 
compared with the other cancer cell lines, stem cells and fibroblasts. ESRP1 exhibited 
roughly the same level of expression in the different cell lines; however, it had an 
extremely low expression in fibroblast. Finally, ESRP2 was expressed at a significantly 
high level in the Hela cell lines.  
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Overall, PTB (PTBP1 and PTBP2) were found to be expressed significantly higher in 
HeLa cell lines, which suggests that a differential expression of PTB might explain the 
splicing pattern of ITGA6 in HeLa cells. On other hand, PTB, RBFOX, MBNL and ESRP 
were expressed at roughly the same levels in MCF7 and MDA-MB231. This suggests 
that the roughly equivalent expression of two isoforms of ITGA6 might explain the 
splicing pattern of ITGA6 in the MCF7 and MDA-MB231 cell lines. PTB, MBNL, RBFOX 
and ESRP1 were expressed at low levels for fibroblast and stem cells, while ESRP1 was 
expressed at a high level in the stem cells (Figure 3.7). 
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Figure 3.7:  Regulation factor expression in different cell lines, stem cells and 
fibroblasts. qPCR was used to quantify expression of PTBP (PTBP1 and PTBP2), 
MBNL1, RBFOX2 and ESRP (ESRP1&ESRP2) in MCF7, stem cell, fibroblast, MDA-
MB231 and Hela cells. Data for the three biological replicates and statistical 
significance were calculated using an independent two-sample t-test, where 
*p<0.05, **p<0.01, ***p<0.0001. 
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3.5 Discussion  
3.5.1Investigation of ITGA6 alternative splicing in different cancer cell lines 
 
In this chapter, I describe an in-depth investigation of the mechanism and regulation of 
endogenous integrin α6 (ITGA6) alternative splicing. Cancer cell lines were selected for 
this study because they are easy to grow and induce to express most genes and 
transcripts. The MDA-MB231 and MCF7 breast cancer cell lines were selected since 
ITGA6 may be expressed in breast carcinoma cells under stress conditions through the 
upregulation of vascular endothelial growth factor (VEGF) expression, either at the 
level of transcription or translation. MDA-MB231 and MCF7 were both originally 
isolated from metastatic breast cancer cell lines; however, MCF7 is less aggressive than 
MDA-MB231 (Chung et al., 2002; Chung et al., 2004a). We also used the HeLa cervical 
cancer cell line since other researchers have used it successfully for studying 
alternative splicing mechanisms. 
 
We started by investigating different cancer cell lines in order to determine the 
differences in their ITGA6 alternative splicing patterns. During differentiation of stem 
cells into fibroblasts, the ITGA6 splicing mechanism switches from inclusion to 
exclusion of the alternative exon (Venables et al., 2013a). In the previous chapter, we 
identified different ITGA6 splicing patterns between the head and tail of a zebrafish 
embryos as well as changes in these patterns during development. In order to 
determine whether different ITGA6 splicing patterns exist in different cell lines, reverse 
transcription polymerase chain reaction (RT-PCR) was performed with a primers 
flanking alternative exon 25 of ITGA6. We found that both ITGA6 splicing patterns 
(inclusion and exclusion) occur for the alternative exon 25, with roughly the same 
percentages of each pattern in both breast cancer cell lines. This suggests that breast 
cancer cell lines are good models to study ITGA6 alternative splicing since, like the 
zebrafish tail, they express two forms of ITGA6. Both isoforms of mRNA may play an 
important role in breast cancer, which is supported by findings that ITGA6a and 
ITGA6b have different functions in cancer stem cells (Goel et al., 2014). The HeLa cell 
line, on other hand, exhibited more exclusion than inclusion of the alternative exon, 
indicating that the shorter form of ITGA6 may be more important in cervical cancer. 
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The HeLa cell line, therefore, might be a good model to study the repression of ITGA6 
alternative splicing.  
 
To summarise, we confirmed that ITGA6 exhibits both alternative splicing patterns in 
the breast cancer cell lines MCF7 and MDA-MB231, and showed for the first time that 
a particular splicing pattern is established in the HeLa cell line. These results confirm 
that cancer cell lines are good models to investigate alternative splicing mechanisms 
controlling ITGA6.  
 
3.5.2 How is ITGA6 alternative splicing regulated? 
 
ITGA6 splicing is regulated by MBNL1 and RBFOX during differentiation of stem cells 
into fibroblasts (Venables et al., 2013). Epithelial splicing regulatory proteins (ESRPs) 
regulate ITGA6 alternative exon splicing in breast cancer cell lines (Chang et al., 2007). 
Therefore, we screened the effects of these known splicing regulatory proteins by 
transfection of siRNA with knockdown of the MBNL1, RBFOX2 and ESRP into cancer 
cell lines. ITGA6 alternative exon 25 was then strongly excluded in the MCF7 and MDA-
MB231 breast cancer cell lines, confirming the previous finding that the ITGA6 
alternative splicing pattern is positively regulated by MBNL1 and RBFOX2 during cell 
differentiation (Venables et al., 2013). Chang et al. (2007) also confirmed that the 
inclusion of the ITGA6 alternative exon is activated by ESRP in breast cancer cell lines.  
 
MBNL1 is involved in myotonic dystrophy and modulates splicing during muscle and 
heart development. RBFOX is a splicing factor that is implicated in the epithelial-to-
mesenchymal transition. ESRP1 and ESRP2 are known to regulate alternative splicing 
during epithelial and mesenchymal differentiation. The splicing activity of RNA-binding 
proteins (RBPs), such as MBNL1, RBFOX and ESRP, are flexible according to their 
binding site (Dredge et al., 2005; Zhang et al., 2008a; Goers et al., 2010; Llorian et al., 
2010). MBNL1, RBFOX and ESRP enhance exon inclusion when they bind downstream 
of the exon but inhibit it when they bind upstream (Figure 3.8). 
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3.5.3 Identification of PTBP as a novel regulator  
 
To fully understand the ITGA6 alternative splicing mechanism, it was important to find 
other regulatory factors which perform opposite functions to ESRP, MBNL1 and 
RBFOX2. Polypyrimidine tract-binding protein (PTBP) is widely known as a repressor. 
Therefore, we performed transfection of siRNA with knockdown of PTBP in breast 
cancer cell lines. Surprisingly, knockdown of PTBP strongly reduced the exclusion of 
exon 25 from ITGA6 in the breast cancer cell lines, which indicates that PTBP inhibits 
the alternative splicing of ITGA6 exon 25. Knockdown of PTBP caused an even greater 
degree of exon inclusion in the HeLa cell line. PTBP1 is widely expressed and belongs to 
a family of RBPs that includes two other paralogs, PTBP2 and PTBP3, which are 
expressed in a more tissue-restricted manner (Noiret et al., 2012). PTBP binds to 
pyrimidine-rich upstream elements in the RNA, which usually act as repressors for the 
alternative splicing of pre-mRNA. However, there are also indications that PTBP can be 
involved in splicing modulation through the binding of downstream pyrimidine-rich 
elements.  
 
 
Figure 3.8: Schematic diagram explaining the  RNA map. This image was adapted 
and modified from (Ule et al., 2006).  
 
Position of enhancers
Position of silencers
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We have observed the ITGA6 alternative splicing patterns after knockdown of the 
regulation factors MBNL1, RBFOX, ESRP and PTBP in triplicate experiments in both the 
HeLa and MCF7 cell lines. The results showed clearly that ITGA6 alternative splicing is 
activated by MBNL1 and inhibited by PTBP in both cell lines; the protein expression 
was tested and confirmed using western blotting. These findings will contribute to the 
understanding the mechanisms of ITGA6 alternative splicing, following the discovery of 
combinatorial control of alternative splicing which describes how proteins can interact 
with each other in order to regulate alternative exon splicing (Smith & Valcarcel, 2000).  
 
The PTBP and MBN1 regulatory factors can also affect gene function via splicing. 
ITGA6a is involved in the proliferation of colon cancer cells (Groulx et al., 2014), and 
ITGA6b is involved in cancer stem cell function by means of the VEGF loop (Goel et al., 
2014). In the VEGF loop, ITGA6b expression is repressed by the ESRP1 factor and 
associated with the VEGF signalling pathway, which represses ITGA6a expression and 
sustains ITGA6b expression in breast cancer (Figure 3.9). Our results thus suggest there 
might be other factors, including PTBP and MBNL1, involved in the splicing of different 
ITGA6 variants. 
 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9: Schematic illustration of the VEGF signalling pathway in cancer stem 
cells  
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The last purpose of this chapter is to describe our investigation of the expression of 
different regulation factors which might affect ITGA6 splicing. We performed 
quantitative polymerase chain reaction (qPCR) to quantitate expression of  
 
PTBP1, PTBP2, MBNL1, RBFOX2, ESRP1 and ESRP2 in the different cell lines. ESRP2, 
PTBP1 and PTBP2 were significantly expressed in the HeLa line. PTBP1 was not 
expressed in fibroblasts nor in stem cells. MBNL1 was expressed in roughly the same 
amounts in the different cell lines, while RBFOX was expressed in greater amounts in 
MCF7. In summary, PTBPs had the highest expression in the HeLa cell line, whereas 
MBNL and RBFOX were expressed at roughly the same levels in HeLa and MCF7. These 
experiments suggested that the expression level of PTBP may be the factor that 
differentiates these cell lines in respect to ITGA6 splicing patterns.  
 
Our overall findings show that ITGA6 exhibits different alternative splicing patterns in 
cancer cell lines, just as in zebrafish fibroblasts and stem cells. The ITGA6 alternative 
exon is activated by the three regulatory proteins MBNL1, RBFOX and ESRP and 
repressed by PTBP regulatory factors. PTBP may also be involved in cell differentiation, 
as it was highly expressed in all cancer cell lines.  
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Chapter 4: Establishment of a minigene system to study 
regulation of the ITGA6 alternative exon  
 
4.1Introduction 
 
In the previous chapter, it was demonstrated that ITGA6 alternative splicing produces 
two isoforms, with exon 25 included or excluded in different cancer cell lines. It was 
also shown that splicing factors, including MBNL1, RBFOX2, ESRPs and PTBPs, 
regulated the ITGA6 endogenous alternative exon. In this chapter, using a minigene 
system, I carried out an in-depth investigation of how the ITGA6 alternative splicing 
mechanism occurs. I hypothesised that establishing a minigene model could help me 
to investigate how ITGA6 alternative exons can be regulated and to identify the 
regulation factors’ binding sites.   
 
The minigene system is the gold standard  method for exploring RNA splicing 
mechanisms (Cooper, 2005). This approach includes the generation of plasmid 
constructs containing parts of genes or entire genes. These constructs are used to 
investigate the process of splicing and the related control mechanisms. Minigene 
constructs were prepared by digesting both the insert (template amplified target 
region) and the vector plasmid with a restriction enzyme (usually selected based on 
making compatible sticky ends); these were then ligated together to obtain the 
constructs. These constructs have the ability to be introduced into different cell lines 
to study the splicing mechanisms. The advantages of minigenes include that they can 
help to test for cell-, tissue- or species-specific splicing effects (Cooper, 2005). The 
minigene method can also test the function of sequences of variable size, from 10 
nucleotides up to several kilobases. Although the minigene method is used to test the 
splicing effect of nucleotide changes on exon inclusion/exclusion, it also can be used to 
test the effect of splicing site alterations, ESE/ESS sites and even in-treatment trials 
(Cooper, 2005).   
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Previously (Venables et al., 2013b), it was found that RBFOX1 and MBNL1 regulate the 
splicing of genes, including ITGA6, in embryonic stem cells and embryos. The RBFOX 
proteins are among the most sequence-specific RNA-binding proteins; and bind to the 
hexanucleotide UGCAUG. The MBNL protein also exhibits high affinity in binding to 
YGCY sites, which are likely to be found approximately every 256 bases. Both RBFOX 
and MBNL1 have been observed to act as repressors for exons when binding 
downstream, whereas they act as activators when binding upstream of the exons. 
ESRPs have also been reported to regulate alternative splicing of ITGA6 in breast 
cancer cell lines. ESRPs have been reported to activate ITGA6 alternative exons 
through binding to UGG-rich motifs downstream of the ITGA6 alternative exon (Goel et 
al., 2014).  
 
In this Chapter, based on the data from the previous Chapter, I aimed to establish an 
ITGA6 minigene, consider the candidate binding sites to investigate the relationship 
between the splicing regulator proteins and assess how they regulate ITGA6 in cancer 
cell lines. Our novel findings in chapter 2 showed that the ITGA6 alternative exon was 
inhibited by PTBPs. PTBP proteins, which generally function as repressors, have an 
affinity for binding at pyrimidine-rich motifs, such as UCUU or CUCUCU, to mediate 
splicing repression in a long list of alternatively spliced pre-mRNAs (Noiret et al., 
2012a). I aimed to identify the PTBP binding site that regulates ITGA6 alternative 
splicing. PTBPs binding upstream of the alternative exon generally repress splicing. In 
the final part of this chapter, I investigate the possibility that PTBPs binding 
downstream of the ITGA6 exon might control splicing patterns of ITGA6 by analysing a 
mutant PTBP binding site in the minigene system. The ITGA6 minigene was 
investigated using cancer cell lines, including Hela, MDA-MB231 and MCF7.  
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4.2 Aims 
The aims of this chapter were to:  
- To establish minigene construct for ITGA6 that would mimic the endogenous 
gene. 
- To investigate how alternative splicing regulators control this ITGA6 minigene   
- To identify the binding site of PTBP downstream of the ITGA6 alternative exon 
and investigate the mechanism of splicing regulation.  
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4.3 Methodology  
4.3.1 ITGA6 Minigene essay: 
4.3.1.1 Primer design   
 
The ITGA6 alternative exon and roughly 332 nucleotides of flanking upstream intron 
and 900 nucleotides of downstream intron sequence were selected for cloning into the 
pXJ41 vector. Primers were designed using Primer3 program in the following link:  
http://bioinfo.ut.ee/primer3-0.4.0/primer3/ . Mfe1 restriction sites were included at 
the 5’ end of each primer. The same procedure was also followed using  different 
different primers to clone different sizes of ITGA6. Primers are listed in Table 4.1.    
 
 
 
 
 
 
 
 
 
 
 
 
4.2.1.2PCR amplification 
 
PCR was performed with a PCR Phusion Kit from Thermo Scientific, following the 
manufacturer’s instructions for 50μl reactions (Table 4.2). Amplification was carried 
out in SensoQuest thermo cyclers by the program shown in Table 4.3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.1: Primers designed to clone different size of ITAG6 regulatory  
Primer  Sequence 
ITGA61.3Kb F TAGCTAGCACAATTGTGCAGGAAGAAACTACCCAAA 
ITGA61.3Kb B TAGCTAGCACAATTGCCCACGTAAATGGTGAAAGG 
ITGA6ShortB TAGCTAGCACAATTGAAAAGCCCATCATGCTGATAA 
ITGA64Kb F TAGCTAGCACAATTGAAGTTGGAGGCAGGACCAG 
ITGA64Kb B TAGCTAGCACAATTGGGGATCAACGGAAGAGAACA 
ITGA6minigeneScreener GCCACTGCATTGTTTCATTG 
  
 
 
 
 
Table 4.2: Components of cloning PCR  
Reagent   Volume μl 
5xCG buffer 10.0 
dNPs 1.0 
10μM Forward Primer 2.5 
10μM Reverse Primer 2.5 
DMSO 1.0 
Template(Human genomic DNA) 1.0 
Phusion DNA Polymerase 0.5 
H2O 31.5 
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4.3.1.3 Gel electrophoresis   
 
PCR products were run on 1.1% agarose gels. The correct product size was cut out and 
purified from the gel using QIAquick Gel Extraction Kit according to manufacturer’s 
instruction (Qiagen). 
 
 
4.3.1.4 Restriction digests  
 
Restriction digests were performed using EcoRI (New England Biolabs) restriction 
enzyme in order to digest the PXJ41 vector. Samples were digested using Mfe1 
restriction enzyme (New England Biolabs) following the manufacturer’s instructions 
(Table 4.4 and 4.5). Digestions were incubated for 3 hours at 37 C. After that, digested 
vector and constructed were ligated following the manufacturer’s instructions table 
and incubated at room temperature overnight (Table 4.6). 
 
 
 
 
 
 
 
Table 4.3: Steps of PCR reaction for cloning  
Program Step Temperature (C) Time(min) Cycle Number 
Heat activation 98 30 seconds 1 
Denaturation 98 10 seconds 32 
Annealing 60 20 seconds 32 
Extension  72 45 seconds 32 
End Stage Extension 72 4 minutes 1 
Cooling 15 ∞  
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4.3.1.5 Molecular cloning  
 
Competent DH5α E.coli and ligation mixes (Inserting DNA and cut Vector pXJ41) were 
mixed, and transformation was achieved using a heat shock protocol.  This protocol 
was done by sequential different incubations on ice, 42°C and ice for 10, 1 and 10 min 
respectively. After that, 1 ml of Luria-Bertani (LB) was added and cells were incubated 
at 37°C for 1 hour. Next bacteria were spread on to a plate of LB agar with 50μg/ml 
ampicillin and incubated at 37°C overnight. Next day, single colonies were picked 
Table 4.4: Constructs Restriction Digest  
DNA 26 μl  
NEBuffer 5μl  
BSA (X10) 5μl 
MfeI restriction enzyme 2μl  
Total 50μl 
 
Table 4.5: Vector Restriction Digest 
DNA 26 μl  
EcoRI buffer 5μl  
BSA (X10) 5μl 
EcoRI restriction enzyme 2μl  
Total 50μl 
 
 
 
 
 
Table 4.6: Component for ligation   
Insert ( digested and clean PCR) 37.9μl  
Vector (PXJ41) 2μl  
T4 DNA Ligase 2μl  
10XT4 Buffer 5μl  
H2O 3.1μl 
TOTAL 50μl 
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individually and screened using primers binding to the vector (Table 4.7) and one 
cloning primer from insert in order to confirm that bacteria contained a correct 
plasmid (Table 4.8 for PCR conditions). Plasmid were picked into 5 ml LB broth plus 
50μg/ml ampicillin and incubated at 37°C overnight in a shaker. The next day, tubes 
were centrifuged at 5,000rpm for 2 minutes in order to get a pellet of cells. Finally a 
QIAprep Mini-prep Kit was used following manufacturer’s instructions in order to 
extract supercoiled plasmid DNA from cells. Plasmid DNA was sequenced using vector 
primers (pXJ41F and pXJ41F, Table 4.7) by Source Bioscience, Oxford. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.7: pXJ41 vector primers for colony screening and for sequencing 
Primer Sequence 
PXJ41F GCTCCGGATCGATCCTGAGAACT 
PXJ41B GCTGCAATAAACAAGTTCTGCT 
 
Table 4.8: Steps for cloning screening PCR  
Step Temperature(C) Time Cycle Number 
Heat activation 95 2 mint 1 
Denaturation 95 1 mint  35 
Annealing 58 1 mint  35 
Extension 72 1 mint  35 
End Stage Extension 72 5 min  1 
Cooling 15 ∞ 1 
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4.3.1.6 Site- directed mutagenesis of the ITGA6 minigenes  
 
Site-directed mutagenesis was conducted in order to mutate the PTBP downstream 
binding site using the wildtype ITGA6 minigene. As a template, primers designed in 
order to delete the PTBP binding site are shown (Table 4.12 and 4.13). Site-directed 
mutagenesis was conducted in two PCR reactions (PCR1 and PCR2) in order to create 
two fragments which overlap desired complementary mutations on opposite strands. 
A third reaction PCR3 was then performed using the fragments from PCR1 and PCR2 as 
template in order to create a full-length insert with the mutation. Finally, the fragment 
containing the mutant on both strands was cloned into empty pXJ41 vector. A figure 
4.1 showing principle of  site-directed mutagenesis  
 
A 50μl reaction was performed for each PCR (PCR1, PCR2 and PCR3) using Phusion Kit 
from Thermo Scientific. The PCR master mix and conditions used are shown in tables 
4.9 , 4.10 and 4.11. Amplifications were carried out in SensoQuest thermo cyclers by 
the program shown in (Table 4.3). A QIAquick PCR Purification Kit was used to purify all 
PCR products following the standard manufacturer’s protocol.  
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Figure 4.1:  Schematic diagram to explain mutagenesis procedure using 
overlap PCR. The first step of the reaction created mutants of fragment by 
using specific primers designed with specific mutations in order to produce two 
overlapping DNA fragments with complementary mutations. These were joined 
by overlap PCR and then cloned into the pXJ41 vector.  
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Table 4.9: PCR1  
  Reagent   Volume μl 
5xCG buffer 10.0 
dNPs 1.0 
Pxj41F   2.5 
Mutant Reverse   2.5 
DMSO 1.0 
Template (wildtype minigene, 20ng/μl) 1.0 
Phusion DNA Polymerase 0.5 
H2O 31.5 
     
Table 4.10: PCR2  
Reagent   Volume μl 
5xCG buffer 10.0 
dNPs 1.0 
pXJ 41B  2.5 
Mutant Forward primer  2.5 
DMSO 1.0 
Template (wildtype minigene, 20ng/μl) 1.0 
Phusion DNA Polymerase 0.5 
H2O 31.5 
 
Table 4.11:PCR3 
Reagent   Volume μl 
5xCG buffer 10.0 
dNPs 1.0 
pXJ 41F  2.5 
pXJ 41B 2.5 
DMSO 1.0 
Template 1 – (PCR 1)  1.0 
Template 2 – (PCR 2)  1.0 
Phusion DNA Polymerase 0.5 
H2O 30.5 
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4.3.2 siRNA transfection 
SiRNA transfections in this chapter  were used to knockdown  PTBP1/2 and MBNL1 
proteins in MCF7 and Hela cells. The protocol of siRNA transfection was described 
previously in chapter 2, methods section.  
 
4.3.3 Western blot 
In this chapter Western immunoblotting was used to confirm PTBP expression after 
transfection with the flag epitope. These used mouse monoclonal antibodies against 
flag (F3165) (1:1000 dilution) as followed by Secondary anti-mouse antibody 
(antibodies at 1:1000 dilution). This was performed following the protocol which was 
described in chapter 2, method section.  
 
 
 
Table 4.12: Primers was used for overlapping PCR (mutagenesis) Del PTBPA 
Primer  Sequence 
PXJ41 F GCTCCGGATCGATCCTGAGAACT 
DelPTBPA B CAA GCC TTCCCC ATC ACTTTA TAG CA CCT CAC CAA GAG AAACAC 
AAC ATTTCC 
DelPTBPA F TGC TAT AAA GTG ATG GGG AAG GCT TG 
PXJ41 B GCTGCAATAAACAAGTTCTGCT 
 
Table 4.13: primers was used for overlapping PCR (mutagenesis) Del PTBPB 
Primer  Sequence 
PXJ41 F GCTCCGGATCGATCCTGAGAACT 
DelPTBPB B TCC CTG TTC AGG GTATTT TTT GTA CTA GTAA CTTTGG TAA GGG ATC 
ATC TTC TGA AGT 
DelPTBPB F CTAGTACAA AAA ATA CCCTGA ACAGGG A 
PXJ41 B GCTGCAATAAACAAGTTCTGCT 
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4.3.4 Transfection 
A variety of plasmids including mutant plasmids and wild type were transfected into 
the MCF7 breast cancer cell line. Transfection was performed using Lipofectamine® 
2000 (Thermofisher). The transfection was performed following the manufacturer’s 
instruction. Table 4.14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
After 24 hours incubation, we checked for transfection efficiency for cell that accepted 
GFP-linked constructs using a fluorescent microscope. Next, cells were washed and 
aliquots pelleted in order to do RNA extractions. 
 
 
 
 
 
 
 Table 4.14: Transfection protocol for ITGA6 minigene: first we mixed (Mix1) and 
(Mix2) together  and incubated for 10-20 min. after that, we spin it for short time 
and then transfected to cell.  
 
Transfection protocol 
Reaction mix 
Components volume Incubation 
time 
Mix 1           Opti-MEM® Medium 80μL 
 
5minutes 
Lipofectamine® 2000reagent 4 μL 
Mix2 Opti-MEM® Medium 80 μL 5minutes 
Plasmid 1 μg 3 μL 
Mix 3 Mix 1 85μL 20 minutes 
Mix 2 83 μL 
Short Centrifugation 
Add 250 μL to each well in 6 well plate  and incubate at 37C overnight 
 
 
 
 
 
 
 
 
 
 
Chapter 4                                     Establishment of a minigene system to study regulation of the 
ITGA6 alternative exon 
90 
 
 
4.4 Results 
4.3.1 ITGA6 alternative exon minigenes respond to splicing control similarly 
to the endogenous ITGA6 alternative exon  
 
Minigene constructs are tools used for the identification of the regulatory factors that 
control splicing and regulate alternative splicing. In the previous chapter, the 
endogenous ITGA6 alternative exon (exon 25) was shown to be regulated by factors 
like MBNL, RFOX, PTB1 and PTB2. I began the work in this chapter with the aim of 
establishing a minigene construct for the ITGA6 alternative exon that could be used to 
investigate regulatory factors.   
Based on preliminary data from (Venables et al., 2013b) the splicing inclusion of the 
ITGA6 exon was enhanced by MBNL1 and RBFOX2; moreover, as (Goel et al., 2014) 
reported, the GU-rich binding site for ESRP protein enhances splicing of the ITGA6 
alternative exon. Given these results, I cloned the alternative exon with the 
surrounding 300 bp upstream and 700 bp flanking downstream intron from genomic 
DNA. The exon and conserved flanking intron sequence was inserted between two 
exons in the pXJ41 plasmid vector to create the minigene construct labelled 
ITGA61.3Kb. This genomic region contains several candidates splicing factor binding 
sites (MBNL1, RBFOX2, ESRPs) that were analysed by Dr Venables (Newcastle 
University; Figure 4.2).  
Subsequently, I transfected the ITGA6 minigene into several cancer cell lines, including 
MDA-MB231, MCF7, and HeLa with plasmid expressing splicing factors in or empty 
vectors as control. RT-PCR was performed using the appropriate primers, which were 
designed to distinguish the minigene transcript from the endogenous one. Each 
transfection was performed in triplicate to observe any changes, and the mRNA 
splicing patterns were analysed using gel electrophoresis. This produced 2 products. 
The upper band included the ITGA6 exon, whereas the lower band represented the 
PCR product without ITGA6 exon 25 (Figure 4.3). This experiment showed that this 
exon is indeed recognised and spliced within the context of the minigene in different 
cell lines with good efficiency compared to the endogenous gene. 
Chapter 4                                     Establishment of a minigene system to study regulation of the 
ITGA6 alternative exon 
91 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CTGCAGGAAGAAACTACCCAAAGCTACAATCAGCAATGTATATACGTTTTCCCTATTAGAATGATTTTTGTCCACAAGATTTCTGTTACAAAGA
GAAAAATCAATGAGCTGACTAGTGTCATCCATATAAATATTTGACCAGAGATGTATGGTGAAGGGTGTATTGAATATGACAATGAAACAATG
CAGTGGCTGTTCATTGTTGGTTGACTGAAAGTGGTCTGTTTGTAAACAAGCCACTAGTAGAAGGCAGATTAAAATTTGAGATGTTCTGTTGTT
TGGCTCTTATACACAAAACTGTAAAATTGACTAAATACCTTGCTTCCTTGTAG 
TG    TGGTTTCTTCAAGAGAAATAAGAAAGATCATTATGATGCCACATATCACAAGGCTGAGATCCATGCTCAGCCATCTGATAAAGAGAGGC 
              TTACTTCTGATGCATAGTATTGATCTACTTCTGTAATTG 
 
GTAATTGATCAATGTTTTTTAATTGCTAGCTGTGGGACCCGCTATGGTTGTGGTGGCTAACTTTAAGAACAACAGCTTGCTATGTGTGTCCCAT
TAACAGATGTTTCCAAATGTCCACACTGGCTTGCCTTGCTTGGATTTGTTTTATTTTATTTCACTTGAAAGCTCAGTTTTTGTTTTTTTTAATGCA
CAGTCTTTCGTTGCAGGTGAGTTATTTTATGTTCTTGTTAAATATCTACCACAGCAATGAAGAAAATTTGCAATATTTGTACACACAAAAAGAG
ACTTTTAGCCCTCCATAGTAGCCCAGTTTGCAATGTGTTATTAATTCGGTATGTAGCATTCCACTAGGGAATTCAAAGATGCATAAGAAATCAT
TCTAGATTTCTTGTCCATTTTGGAATTTTCCACAGATAGAAGCTGTGTCGACCGCCTAATTAACCTGTTGCATGTTGGAAATGTTGTGTTTCTCT
TGGTGAGGCTTCCTCACTGTCATCTTTTTGTTCTCTTTGCTATAAAGTGATGGGGAAGGCTTGGAATGCTTTTTACTGTTGCTCAGGAATCGTTT
TATGCTAGCTAAGCATGCAACTTCCATTTCCTGCATGTCTCCTACAGGTCAAAGACCATTACAACAAACTGATTATCAGCATGATGGGCTTTTA
TGGCCAACTTCAGAAGATGATCCCTTACCAAAGTTACCTTCCATCTACAAAATTCTAGTACAAAAAATACCCTGAACAGTTTTTATTGCAATAT
GTTGTGATGGAGTTTGACCATATTTCATGTATCCAGAGATTTTATCCAACCTTGGATCTCAGTTGATTTTAAATTCAAGTTTCTCTTATTTGGAA
ATACATGGAAATAGGAATTGCTAGTGATCCCTTTCACCATTTACGTGGG 
AGCATG         FOX weak site   
TGCATG         FOX   strong site 
TGCT              Strong MBNL site 
TGCC              Medium MBNL site 
CGCC              Weak MBNL site 
TG                    ESRPs site 
 
Figure 4.2: Sequence of the human alternative exon of ITGA6 and surrounding 
intron sequences. The alternative exon is shown in red font. RBFOX binding sites 
are shown in red highlight (strong site) and pink (weak site). MBNL sites (YGCY) are 
highlighted blue (strong site) green (medium) and yellow (weak site).  
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Figure 4.3. Establishment of a minigene system to study regulation of the ITGA6 
alternative exon. To test if the ITGA6 alternative exon is repressed by PTB, I made 
a minigene  construct  for the ITGA6 alternative exon along  with the surrounding 
introns   and transfected this  into  different cancer cell lines. After RT-PCR and gel 
electrophoresis, the lower band represented short mRNA isoform (excluded exon) 
whereas, upper band represented the long isoform (inclusion exon).    
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4.4.1.1 A ITGA61.3Kb is an appropriate minigene to study the regulatory 
factors that control ITGA6 alternative exon 25  
 
The pervious result indicate that the ITGA6 minigene mimics the endogenous ITGA6 
alternative exon. Given these results, I sought to further identify a good minigene that 
would define the response regions that are bound by the splicing factors. 
Subsequently, with help from Dr Venables, a strategy was established to clone 
different sizes of the ITGA6 alternative exon with variable lengths of surrounding 
introns to obtain the ITGA6 minigene that would best facilitate investigation of the 
splicing mechanism. 
  
Based on bioinformatics data from Dr Venables, I decided to clone the ITGA6 
alternative exon with different sizes of surrounding introns, whether upstream or 
downstream of the alternative exon. I cloned a larger minigene containing a greater 
amount of the intronic sequence to determine whether this contained further 
regulatory sequences; in addition, I cloned short minigenes in the hope that they 
would be as useful to allow a more precise definition of the control regions. For the 
longer clone, I amplified the exon with 1500 bp upstream and 2300 bp downstream 
intron from the genomic DNA, and cloned  this into a pXJ41 exon trap plasmid, to 
create the minigene called ITGA64Kb (Figure 4.4). I also cloned ITGA6short, an ITGA6 
alternative exon with deletions removing the expected binding sites for RBFOX and 
MBNL, with 300 bp upstream and 225 bp downstream flanking intron (Figure 4.4).  
 
Following this, the two minigenes ITGA64Kb and ITGA6short were transfected in 
cancer cell lines, including Hela, MDA-MB231 and MCF7. RT-PCR was performed using 
appropriate primers designed on the β globin exons of the pXJ41 plasmid vector to 
discriminate the minigene transcript from the endogenous context. Each transfection 
was performed in triplicate to observe any change in splicing pattern, and the mRNA 
splicing patterns were analysed using gel electrophoresis. The upper band included 
ITGA6 exon), whereas the lower band represented the PCR product without ITGA6 
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exon (Figure 4.5). The ITGA64kb showed variable exon inclusion between the cell lines, 
whereas ITGA6short did not show exon inclusion in any cell lines. Overall the original  
ITGA61.3kb minigene showed the best exon inclusion when compared with the two 
other ITGA6 minigenes, and showed similar patterns of splicing compared to the 
endogenous ITGA6. 
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Figure 4.4: Cloning a series of constructs of different lengths containing 
the ITGA6 alternative exon and surrounding intron sequences. a) A 
sequence of ITGA6 alternative exons (red font) and surrounding intron 
sequences (black font). The yellow line represents ITGA6short region 
cloning. The ITGA61.3Kb cloning region is shown in blue, while the ITGA64kb 
cloning region is shown in red. b) A diagram showing the different cloning 
regions of the ITGA6 alternative exon.  
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Figure 4.5: Analysis of ITGA6 minigene constructs. The agarose gel shows PCR 
products made from of cDNA of HeLa, MDA-MB231 and MCF7 cells transfected 
with ITGA6 4Kb , ITGA6 1.3kb and ITGA6short minigenes. The upper band 
represents the inclusion ITGA6 alternative exon (318 bp), which appears only in 
ITGA61.3kb and ITGA64Kb. The lower band represents the exclusion ITGA6 
alternative exon (vector without insertion) (188 bp). 
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4.4.2 The ITGA6 alternative exon encoded with a minigene response to 
changes in regulation factors similarly to the endogenous ITGA6 alternative 
exon . 
 
The ITGA61.3kb minigene construct showed strong inclusion for the alternative ITGA6 
exon in the MCF7 and MDA-MB-231 cancer cell lines compared to HeLa cells. To 
determine the factors that regulate the ITGA6 alternative exon in endogenous, I used 
the ITGA61.3kb minigene construct. This also had the advantage of being smaller than 
the ITGA64kb minigene insert, so there was less sequence to consider binding sites 
within. 
 
Based on our findings in chapter 3, where it was shown that the ITGA6 alternative exon 
is activated by RBFOX2, MBNL1, ESRPs and repressed by PTBPs, I sought to determine 
whether these potential splicing factors regulate the ITGA61.3Kb minigene in the cell 
lines. The MCF7 cell line, in which ITGA6 can be expressed, was shown to be a good 
model for studying endogenous alternative splicing of ITGA6 since it expresses both of 
the two mRNA isoforms. The MCF7 cell lines also showed successful expression for the 
ITGA6 minigene. Subsequently, the ITGA6 minigene was transfected into MCF7 cells 
the same time as these same cells were co-transfected with PTBP, MBNL1, RBFOX2 
and ESRP siRNAs to knock down these endogenous proteins. RT-PCR was performed 
using the appropriate primers, which were designed to distinguish the minigene 
transcript from the endogenous. In the upper band, the minigene-derived transcripts 
contain the alternative exon, whereas the lower band represented the PCR product 
without exon insertion. Pattern of splicing from the minigene ITGA61.3Kb alternative 
exon shifted clearly from inclusion to more exon exclusion with the knockdown of 
MBNL1, while the knockdowns of ESRPs and RBFOX2 did not show an effect. Similar 
results were obtained for the endogenous mRNA. In addition, siRNA of PTBPs did not 
show a clear effect for either the minigene or endogenous gene. Overall, the 
knockdown of MBNL1 alone showed a clear shift in alternative exons compared to the 
non-siRNA control (Figure 4.6). 
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Based on novel findings presented in the previous chapter, it was predicted that PTBPs 
act as repressors for the endogenous ITGA6 alternative exon. The PTBP knockdown 
removed all inhibition of ITGA6 exon inclusion in MCF7; however, the splicing shift was 
small due to the high baseline level of exon inclusion in the cell line. To observe a 
greater shift, I turned to the HeLa cell line, which exhibits a low level of exon inclusion. 
Since PTBs were shown to clearly inhibit the endogenous ITGA6 alternative exon in the 
HeLa cell line, I sought to determine whether I could also observe the same inhibition 
using the ITGA6 minigene. Thus, I co-transfected the ITGA6 minigene into HeLa cells 
with double knockdown of PTB1 and PTB2. RT-PCR was performed using primers 
designed across the alternative exons for endogenous ITGA6, and to detect mRNAs 
from the minigene respectively. As expected, ITGA6 splicing shifted towards the long 
form with double knockdown of PTB1 and PTB2. Moreover, as anticipated, PTB1 and 
PTB2 shifted splicing to the short form in the ITGA6 minigene (Figure 4.7). 
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Figure 4.6: Effect of knock down of splicing regulation factors on expression of 
the ITGA61.3Kb minigene construct in the MCF7 cell line. a) The endogenous 
ITGA6 alternative splicing patterns after knocking down (PTBP1/2, MBNL1, 
RBFOX2 and ESRP1 in MCF7 cells. The upper band (377 bp) represents the long 
form (with inclusion of the alternative exon), whereas the lower band (249 bp) 
represents exclusion of the alternative exon. b) Agarose gel of RT-PCR using 
minigene primers around the ITGA6 alternative exon. A PCR product (ITGA61.3Kn 
minigene) including the alternative exon is shown in the upper band (inclusion 
exon) and the lower band (exclusion exon).  
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Figure 4.7: The ITGA6 1.3kb minigene construct responds to knock down of 
PBTBP1 and PTBP2 similarly to the endogenous gene.  Agarose gel shows. a) The 
endogenous ITGA6 alternative exon knockdown PTB1 and PTB2. The upper band 
represents the exon inclusion (377 bp), whereas the lower band shows the 
exclusion of the alternative exon (247 bp). b) RT-PCR using minigene primers 
around the alternative ITGA6 exon. The upper band represents exon inclusion 
and the lower band exon skipping. Double knockdown of PTB1 and PTB2 in ITGA6 
causes a shift from the lower band to the upper band for both the minigene and 
endogenous ITGA6. 
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4.4.2.1 Confirmation of PTB as a novel regulator of the ITGA6 alternative 
exon 
 
The ITGA6 1.3kb minigene construct showed a response to two regulatory factors, 
namely MBNL1 and PTBP1, in the MCF7 and HeLa cell lines, respectively. PTBP acted as 
a repressor of the ITGA6 alternative exon, whereas MBNL1 acted as an activator for 
both the minigene and endogenous mRNA. Therefore, these proteins contributed to 
the inclusion or exclusion of ITGA6 exon 25.  
 
The prediction that the knockdowns for these proteins cause inclusion or skipping for 
exon 25 of the ITGA6 minigene was previously considered in this work (4.4.2). In this 
section, complementary experiments on the overexpression of these regulatory 
factors, including PTBP and MBNL1, was carried in the MCF7 cell line out to confirm 
the functional role of these proteins. I performed co-transfection of the ITGA6 
minigene (ITGA61.3Kb) and expression vectors encoding PTBPs (PTBP1, PTBP2) and 
MBNL1 in triplicate in a breast cancer cell line. RT-PCR was performed by using specific 
primers across flanking exons for the minigene. The upper band includes the ITGA6 
exon, whereas the lower band represented the PCR product without ITGA6 exon. 
Multicapillary QIAxcel electrophoresis was used to calculate the concentration ratio 
between the two forms of ITGA6 splicing. The percentages of alternative splicing 
patterns were calculated and plotted on a graph. 
 
The overexpression of PTBP1 co-transfected with the ITGA6 minigene (ITGA61.3Kb)  
showed a significant decrease in per cent splicing in (PSI) of the ITGA6 minigene exon 
25 from 14 to 4%, compared with the ITGA61.3Kb minigene alone (Figure 4.8 ). The 
overexpression of PTBP2 co-transfected with the ITGA6 minigene did not show a 
change. As expected, overexpression of MBNL1 with the ITGA61.3Kb minigene showed 
a significant increase in PSI for the ITGA6 minigene alternative exon, changing from 14 
to 30% inclusion, compared with the minigene alone. Overall, these results confirm 
that the ITGA6 minigene is activated by MBNL1 and inhibited by PTBP1.    
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Figure 4.8:  Overexpression of splicing regulation factors with ITGA61.3Kb 
minigene construct in the MCF7 cell line.  Bar chart shows the percentage splicing 
inclusion (PSI) of the ITGA6 minigene with overexpression constructs encoding 
PTBs & MBNL (blue) compared with ITGA6 wild type GFP (red). MBNL has higher 
PSI compared to GFP, whereas PTBP1 has less. Data represents the mean of three 
biological replicates in each case. Statistical significance was calculated using an 
independent two-sample t-test, where *p<0.05, **p<0.01, ***p<0.0001.  
Capillary gel electrophoresis shows MBNL drives more inclusion (‘a’ form) 
whereas PTB1 represses the ‘a’ exon, comparing with coexpression of GFP. 
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4.4.3 Effects of PTBP overexpression/KD in different cell lines on splicing 
pattern from the minigene  
 
In previous experiments, I investigated the splicing regulators for the ITGA6 alternative 
exon in cancer cell lines. MBNL1, RBFOX2, ESRPs and PTBPs regulated the ITGA6 
alternative exon. Following on from that work, MBNL1 and PTBPs were shown to 
regulate the splicing of both the minigene-encoded and endogenous ITGA6. Since 
PTBPs represent novel, not previously reported regulators for the ITGA6 alternative 
exon, I sought to investigate alternative splicing regulation in more detail  and identify 
the binding sites of the PTBP regulatory factor.    
 
To test the hypothesis that an RNA binding site for PTBP proteins caused skipping of 
the exon, it was important to find a good cell line for more investigation. Experiments 
on silencing and overexpression of PTBP proteins were conducted on cancer cell lines 
to identify the binding sites for PTBPs. In the MCF7, MDA-MB237 and HeLa cell lines, I 
performed co-transfection of the ITGA6 minigene (ITGA61.3Kb) and expression vectors 
encoding PTBPs (PTBP1, PTBP2); at the same time, the ITGA6 minigene was co-
transfected with PTBP siRNAs to knockdown protein. Following this, RT-PCR was 
performed using specific primers across the flanking exons. Different patterns between 
two RT-PCR bands were observed using multicapillary QIAxcel gel. The percentages of 
the alternative splicing patterns were calculated and plotted on a graph (The method 
of calculation is described in the method results 3.3.3).     
 
By observing the knockdown and overexpression of PTB proteins, it was found that the 
ITGA6 minigene showed a significant increase in included exon after knockdown of 
PTBPs and a significant decrease in the alternative exon with overexpressed PTBPs 
compared with the ITGA6 minigene alone in the MCF7 cell line (Figure 4.9a). In the 
HeLa cell line, inclusion the alternative exon of the ITGA6 minigene was significantly 
decreased with overexpression of PTPBs, compared with the ITGA6 minigene alone. 
However, knockdown of PTBPs with the ITGA6 minigene did not show significant 
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difference for the alternative exon compared with the ITGA6 minigene transfected 
alone (Figure 4.9b). As expected, in MDA-MB-231 cells the alternative exon of the 
ITGA6 minigene was significantly decreased with the overexpression of PTBPs, whereas 
it showed no change with knockdown PTBPs compare with the ITGA6 minigene 
alone(Figure 4.9c). Hence, overall, MCF7 was the only cell line that showed a 
significant alternative exon of ITGA6 with overexpression and silencing of the PTBP 
regulatory factor 
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4.4.4 The downstream binding site for PTB represses splicing of the ‘a’ exon 
through RNA protein interactions 
 
Since the alternative exon of the ITGA6 minigene successfully exhibited a significant 
response to knockdown and overexpression of PTBPs in the MCF7 breast cancer cell 
line, I decided to investigate whether PTBP proteins could bind directly to ITGA6. To 
investigate the binding site, it was important first to identify candidate binding sites 
using bioinformatics. It has been reported in several studies that PTBPs binding 
upstream or within the alternative exon act as a splicing repressor (Amir-Ahmady et 
al., 2005). However, an analysis of PTBP binding sites at the ITGA6 alternative exon 
using a CLIP experiment, which was performed by Dr C.W. Smith (Cambridge 
University), identified two candidate binding sites for PTBPs downstream of the ITGA6 
alternative exon (Figure 4.10 a).     
 
To investigate whether these putative binding sites for PTB were required for splicing 
repression of the ITGA6 alternative exon, PTBP candidate binding sites 
(CTTCCTCACTGTCATCTTTTTGTTCTCTT and TCCATCTACAAAATT) were mutated within 
the wildtype ITGA6 minigene. To do this, I used overlapping PCR with specific primers 
to delete the first PTBP binding site (Del PTBPA). For deletion of the second PTBP 
binding site (Del PTBPB), I used gblock to synthesise the sequence after the PTBP 
binding site (TCCATCTACAAAATT) and directly overlap it with the upstream product. 
Overlapping PCR and gblock cloning are explained in the methodology section.  
 
After generating minigenes with deletions for the PTBP binding sites, each minigene 
was transfected into the MCF7 breast cancer cell line. After 48 hours, the cells were 
harvested and the RNA was reverse transcribed. Following this, RT-PCR was performed 
using specific primers across the flanking exon. Splicing patterns were observed by gel 
electrophoreses, and the concentration of inclusion of the ITGA6 minigene alternative 
exon was calculated using a multicapillary QIAxcel gel electrophoresis device. The 
concentration of inclusion was calculated and presented as a graph (Figure 4.10b).    
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The results of the mutant minigene transfection are shown in Figure 10b. 
Unexpectedly, mutants removing the downstream binding site for PTBPs, whether Del 
PTBPA or Del PTBPB, showed less inclusion for the alternative exon from minigene 
compared with wildtype ITGA61.3kb. In other words, there was a small reduction in 
splicing activation by PTBPs in mutants A and B. This means that although PTB overall 
expression represses the alternative exon of ITGA6, these actual binding sites activate 
alternative exon as well . 
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Figure 4.10: effect of mutating the PTB binding sites downstream of the ITGA6 
exon.  a) Sequence of the human alternative exon of ITGA6 and surrounding 
intron sequences with deletion for candidate PTB sites ( Del A & Del B) in 
downstream intron.  b) Bar chart shows the PSI level of the ITGA6 minigene with 
del A (red)  &del B (pink) giving  less inclusion  for  the alternative  exon compared 
with  wild type ITGA61.3 GFP (green). This means that even though PTB 
expression represses exon ‘a’ ( exon 25), these binding sites are activating. 
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4.4.4.1 PTBP may function in ITGA6 splicing by sequestering other splicing 
regulators 
 
PTBPs usually controls alternative splicing based on its binding site location. While 
PTBPs act as a repressor when binding upstream or within the exon, they function to 
activate splicing from downstream binding sites (Amir Ahmed et al., 2005)(Boutz et al., 
2007, Llorian et al., 2010, Xue et al., 2009) . Since deletion of PTB binding sites 
downstream of the ITGA61.3kb alternative exon showed the opposite response (less 
inclusion for alternative exon), we predict that these sites normally activate the ITGA6 
exon, but that protein interactions of PTB may act to repress the ITGA6 alternative 
exon by impacting other splicing regulators. 
 
PTBPs have four RNA recognitions motifs (RRMs), which recognise pyrimidine-rich 
RNAs and allow splicing regulation. It has been reported that all PTBP RRMs can 
specifically recognise a CUCUCU ligand based on the NMR structure (Mickleburgh et al., 
2014). RRM1 and RRM3 recognise the motif YCU, whereas RRM2 recognises core CU. 
RRM4 is the least specific motif, with recognition of 5-YC-3 (Mickleburgh et al., 2014). 
PTBs can also bind to other splicing regulators and perhaps inhibit their function 
(Figure 4.11).  
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To find out what part of PTB protein is responsible for responsible for repressing the 
ITGA6 exon, PTBPs with several mutant motifs, including RRM1, RRM2, RRM3 and 
RRM4, were generously provided by Dr C.W.J. Smith. All constructs were cloned within 
the MluI/AvrII sites of the FLAG-NLS-MS2-ABM vector, which originates from the 
pCINeo and contains a FLAG tag in the 5’ end of the gene and a NLS signal at the 3’ end. 
The ITGA61.3kb minigene alternative exon, which was previously shown to be 
inhibited by PTBPs, was co transfected with expression vectors encoding PTBPs in the 
MCF7 breast cancer cell line (figure 4.12a). These expression vectors encoded different 
RRM mutants in the following order: WT; mutant 1, 2, mutant3, 4; mutant 1, 2, 3, 4; 
RRM12L (N-term half); and RRM34 (C-term half).  The transfection approach is 
explained in the methods section.  
 
Figure 4.11: PTB protein structure. a) Schematic illustration of PTB RNA binding 
sites including RRMA1 (red) RRM2 (grey) RRM3 (yellow) and RRM4 (green). Each 
RRM motif has different binding affinity for pyrimidine-rich sequences on 
mRNA. b) Model of the interaction PTB four motifs with RNA.  Image adapted 
from(Sawicka et al., 2008b) 
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It was Important to confirm that at the protein level, PTBS RRM1,2, RRM3,4 and 
RRM1234 were generated with Flag. To accomplish this, western immunoblotting was 
performed using mouse monoclonal antibody against Flag and rabbit monoclonal 
against Actin as the control. On western blotting, the expression of the flag protein 
was only detected and corresponded to the expected size of 55 kDa in the WT. 
However, the RRM mutants (RRM1,2 RRM3,4 and RRM1234) did not show any bands 
(Figure 4.12b).    
.   
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Figur4.12: Effect of different RRM mutation upon to PTB inhibitor a) schematic 
illustrate  mutant  site at 4 domain PTB binding sites, and table shows the location 
of the mutant. b) ITGA6 minigene with different PTB motifs bind mutant was 
confirmed in MCF7 cell lines. PTB with different mutants has not expressed their 
compared with the wild type WT control.) Western blotting for PTBP different 
mutant expression with flag. It does not show any expression compare with WT.  
 
Chapter 4                                     Establishment of a minigene system to study regulation of the 
ITGA6 alternative exon 
113 
 
 
4.5 Discussion  
 
In this chapter, I explained the design, assembly and validation of the ITGA6 minigene 
to study the mechanism of ITGA6 alternative splicing and its use to identify a binding 
site for the splicing regulator PTBP. The use of a minigene assay provided the flexibility 
to identify information about the protein-RNA interaction via mutating and rearranging 
the gene sequence. Many studies have used minigene assays for splicing, such as 
(Steffensen et al., 2014) for the BRCA1 gene,  (Ulzi et al., 2014) for the CLCN1 gene and  
(Grellscheid et al., 2011)  for Tra2β target HIPK3. 
 
This chapter’s first aim was to establish an ITGA6 minigene that mimics the 
endogenous ITGA6 alternative exon. To test this aim, the minigene was created using a 
genomic DNA fragment including the ITGA6 alternative exon and surrounding intron, 
which included cloning RNA-binding proteins’ candidate sites. This construct 
transfected into standard cancer cell lines like MCF7, MDA-MB237 and HeLa cells. In 
vitro expression and alternative splicing of minigene mRNA transcripts were confirmed 
and found to have a similar splicing pattern to the endogenous gene. This provides 
strong evidence that the ITGA6 minigene represents a good model for a splicing study, 
due to showing roughly the same percentage of ITGA6 alternative exon inclusion as 
the endogenous gene after transfection into three different cancer cell lines. 
 
Therefore, to get a good minigene to investigate the ITGA6 alternative exon, I made 
two additional ITGA6 minigene constructs with variable intronic lengths (ITGA64K.B 
and ITGA6 short). These two minigenes were transfected to standard cancer cell lines 
as well as to the original ITGA6 minigene (called ITGA61.3KB). ITGA61.3K.B was still the 
best model in the three cancer cell lines due to the consistency and high efficiency of 
minigene expression in multiple independent transfections of the exon inclusion 
expression compared with the ITGA64Kb and the ITGA6 short construct. ITGA64k.b 
expression was not consistent in all cell lines, and this might be due to the intron 
length, which is 1413 nucleotides upstream and 1081 nucleotides downstream. The 
Houston Departments of Pathology and Molecular and Cellular Biology (2005) reported 
that the primary elements for regulating alternative splicing are typically within 200–
Chapter 4                                     Establishment of a minigene system to study regulation of the 
ITGA6 alternative exon 
114 
 
300 nucleotides upstream and/or downstream of the regulated exon. Furthermore, 
ITGA6 short did not show any exon inclusion. This could be due to the short length of 
downstream alternative exon, which is 198 nucleotides. 
 
This chapter’s second aim was to investigate factors that regulate the ITGA6 
alternative exon. MBNL1, RBFOX2 and ESRPs activated the endogenous ITGA6 
alternative exon, whereas PTBP was a repressor for ITGA6 alternative exon. Therefore, 
I performed a co-transfection siRNA knockdown for PTBP, MBNL1, RBFOX2 and ESRP 
regulation factors with the ITGA6 minigene in MCF7 and HeLa cell lines. MBNL1 and 
PTBP regulated the ITGA6 minigene alternative exon just like the endogenous one. 
MBNL1 activated ITGA6 minigene alternative exon, whereas PTBP repressed the ITGA6 
minigene alternative exon. This result was confirmed by transfected ITGA6 minigene 
with overexpression constructs for PTBs and MBNL in MCF7. This demonstrated that 
MBNL drives more inclusion exon 25  (‘a’ form), whereas PTBP2 represses the  exon25 
when compared with the co-expression of GFP.  
 
These results showed that ITGA61.3kb minigene is a potential paradigm for the 
concept of combinatorial control of alternative splicing (Smith & Valcarcel, 2000). The 
MBNL protein has a high affinity in binding to YGCY sites (TGCT Strong MBNL site, TGCC 
Medium MBNL site, CGCC Medium MBNL site). The alternative exon of ITGA6 minigene 
was activated by MBNL1, consistent with MBNL1 being bound downstream of the 
alternative exon. The study supports MBNL1 acting as an activator when it is bound 
downstream of the alternative exon. (Figure 4.13 suggestions the possible binding site 
for MBNL1 in ITGA6 ) 
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However, PTBPs were also confirmed as novel regulators (repressors) of the ITGA6 
alternative exon after their overexpression. Since PTBP is a novel regulator for ITGA6, I 
used the end of this chapter to investigate PTBP binding and how it can regulate the 
ITGA6 alternative exon. PTB overexpression and knockdown was combined with ITGA6 
minigene co-transfection into three standard cancer cell lines, including MCF7, MDA-
MB231 and HeLa cell lines. Of these, the MCF7 breast cancer cell line was the best cell 
line for studying PTBP regulation for the ITGA6 minigene due to the high-quality 
response to both PTBP overexpression and depletion. In other words, MCF7 cell lines 
were the only cell lines that responded to both PTBP overexpression and depletion.  
 
 
Figure 4.13. Illustration of the possible binding site for MBNL1 in ITGA6. The 
sequence represents the ITGA6 alternative exon (in red) with surrounding introns. 
MBNL1 candidate bind sites are in yellow, blue and green boxes. The diagram 
underneath represents where MBNL1 binds in order to activate ITGA6 alternative 
exon. 
CTGCAGGAAGAAACTACCCAAAGCTACAATCAGCAATGTATATACGTTTTCCCTATTAGAATGATTTTTGTCCACA
AGATTTCTGTTACAAAGAGAAAAATCAATGAGCTGACTAGTGTCATCCATATAAATATTTGACCAGAGATGTATGG
TGAAGGGTGTATTGAATATGACAATGAAACAATGCAGTGGCTGTTCATTGTTGGTTGACTGAAAGTGGTCTGTTTG
TAAACAAGCCACTAGTAGAAGGCAGATTAAAATTTGAGATGTTCTGTTGTTTGGCTCTTATACACAAAACTGTAAA
ATTGACTAAATACCTTGCTTCCTTGTAG 
 
      TGTGGTTTCTTCAAGAGAAATAAGAAAGATCATTATGATGCCACATATCACAAGGCTGAGATCCATGCTCAGCCATCTGATAAAGAGAGGC 
               TTACTTCTGATGCATAGTATTGATCTACTTCTGTAATTG 
 
GTAATTGATCAATGTTTTTTAATTGCTAGCTGTGGGACCCGCTATGGTTGTGGTGGCTAACTTTAAGAACAACAGC
TTGCTATGTGTGTCCCATTAACAGATGTTTCCAAATGTCCACACTGGCTTGCCTTGCTTGGATTTGTTTTATTTTATT
TCACTTGAAAGCTCAGTTTTTGTTTTTTTTAATGCACAGTCTTTCGTTGCAGGTGAGTTATTTTATGTTCTTGTTAAA
TATCTACCACAGCAATGAAGAAAATTTGCAATATTTGTACACACAAAAAGAGACTTTTAGCCCTCCATAGTAGCCC
AGTTTGCAATGTGTTATTAATTCGGTATGTAGCATTCCACTAGGGAATTCAAAGATGCATAAGAAATCATTCTAGA
TTTCTTGTCCATTTTGGAATTTTCCACAGATAGAAGCTGTGTCGACCGCCTAATTAACCTGTTGCATGTTGGAAATG
TTGTGTTTCTCTTGGTGAGGCTTCCTCACTGTCATCTTTTTGTTCTCTTTGCTATAAAGTGATGGGGAAGGCTTGGA
ATGCTTTTTACTGTTGCTCAGGAATCGTTTTATGCTAGCTAAGCATGCAACTTCCATTTCCTGCATGTCTCCTACAG
GTCAAAGACCATTACAACAAACTGATTATCAGCATGATGGGCTTTTATGGCCAACTTCAGAAGATGATCCCTTACC
AAAGTTACCTTCCATCTACAAAATTCTAGTACAAAAAATACCCTGAACAG 
ITGA6  
25
MBNL1
downstreamupstream
YCGY 
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This might be due to the high expression of PTBP in MCF7. Thus, MCF7 was shown to 
be a good cell line for studying splicing in minigenes.  
 
PTBP is well characterised as a splicing suppressor for alternative exons, particularly in 
muscles and neuron tissues in which PTB is high. The same studies also reported that 
PTB acts as a repressor (Smith & Valcarcel, 2000) for exon 3 of the ITM gene. Other 
studies (Smith & Valcarcel, 2000) showed that PTB represses alternative exons in 
different genes. PTB usually binds at pyrimidine-rich motifs, such as UCUU or CUCUCU, 
in the RNA at upstream (near to the 3’ splice site) alternative exon in brain and neuro 
tissues. To test and identify the PTB-binding sites, we used CLIP-seq results that 
identified the direct RNA targets for PTB-binding sites in ITGA6 minigene sequences 
from our collaboration with Dr Smith’s lab at Cambridge University. They had shown 
that PTB candidate-binding sites were in downstream alternative exon from ITGA6, 
with the intronic regions near the 5’ splice site (Figure4.15). Also downstream of the 
alternative exon are PTB consensus binding sites. However, according to current rules, 
these would be predicted to activate the 25 alternative exon, not repress it. To test 
whether these downstream sites could repress 25 exon, we mutated them by deleting 
downstream PTBP candidate sites (Del A & Del B) from an ITGA6 minigene and 
transfected it into MCF7 cells. The ITGA6 alternative exon had less inclusion than with 
the wild-type minigene.  
 
From our siRNA and over-expression data for PTBP proteins, we expected to see more 
inclusion for the alternative exon after binding site mutation; however, with mutated 
PTB-binding sites, we saw less inclusion for the alternative exon. This means that even 
though PTB expression represses the alternative exon overall, these downstream 
binding sites are activating.  
 
Several different mechanisms have been proposed for how PTB represses splicing, 
including PTB interaction with other regulatory proteins. We hypothesise that PTB 
might interact with other proteins to repress the ITGA6 alternative exon, and 
specifically to titrate away splicing activator proteins needed for this activation. This 
would be due therefore to protein-protein interactions, not protein-RNA interactions.  
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PTB binds to RNA on four RNA-recognition motifs, which recognise pyrimidine-rich 
RNAs. To determine what part of PTB proteins was responsible for repressing ITGA6 
exon, we transfected PTB with a mutant in different RRM (RRM1.RRM2, RRM3 and 
RRM4, which were generated and provided by Dr C. W. Smith) in MCF7 cancer cell 
lines. However the confirmation test for those mutations in protein levels did not show 
expression. 
 
Taken as a whole, these results indicate that PTB might interact with other regulatory 
proteins to repress the ITGA6 alterative exon. Other studies have shown that PTBP can 
repress alternative exon splicing via interaction with other regulatory factors, including 
Nova-1 and Nova-2 (Polydorides et al., 2000), Raver1 (Gromak et al., 2003) and MRG15 
(Luco et al., 2010). PTB-binding sites are located downstream of the ITGA6 alternative 
exon within a cluster of binding sites for other proteins, including MBNL1, RBFOX and 
ESRPs. As a result, PTB might also follow the mechanism that suggests MBNL1 and PTB 
cooperate to repress alternative exon during splicing. (Gooding et al., 2013) conducted 
a study that showed MBNL1 interacts with PTB to repress the splicing of TPM1 exon 3. 
Combining our findings with those of other studies, such as (Gooding et al., 2013), we 
predict that PTB might interact with other regulatory proteins, likely MBNL1 or RBFOX, 
to repress the ITGA6 alternative exon as a complex (Figure 4.14). 
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Figure 4.14 Schematic to illustrate the how splicing regulator proteins and 
their binding sites regulate the ITGA6 exon. The ITGA6 alternative exon  is in 
black, and the diagram shows the binding sites and protein interactions, and 
how might they regulate ITGA6 alternative exon. In this model, PTBP inhibits 
the function of MBLN. 
RBFOX
TGCAGGAAGAAACTACCCAACTGCAGGAAGAAACTACCCAAAGCTACAATCAGCAATGTATATACGTTTTCCCTATTAGAATGATTTTTGTCCACAAGATTTCTGT
TACAAAGAGAAAAATCAATGAGCTGACTAGTGTCATCCATATAAATATTTGACCAGAGATGTATGGTGAAGGGTGTATTGAATATGACAATGAAACAATGCAGTGG
CTGTTCATTGTTGGTTGACTGAAAGTGGTCTGTTTGTAAACAAGCCACTAGTAGAAGGCAGATTAAAATTTGAGATGTTCTGTTGTTTGGCTCTTATACACAAAAC
TGTAAAATTGACTAAATACCTTGCTTCCTTGTAG 
 
TGTGGTTTCTTCAAGAGAAATAAGAAAGATCATTATGATGCCACATATCACAAGGCTGAGATCCATGCTCAGCCATCTGATAAAGAGAGGCTTACTTCTGATGCAT
AGTATTGATCTACTTCTGTAATTG 
 
GTAATTGATCAATGTTTTTTAATTGCTAGCTGTGGGACCCGCTATGGTTGTGGTGGCTAACTTTAAGAACAACAGCTTGCTATGTGTGTCCCATTAACAGATGTTT
CCAAATGTCCACACTGGCTTGCCTTGCTTGGATTTGTTTTATTTTATTTCACTTGAAAGCTCAGTTTTTGTTTTTTTTAATGCACAGTCTTTCGTTGCAGGTGAGT
TATTTTATGTTCTTGTTAAATATCTACCACAGCAATGAAGAAAATTTGCAATATTTGTACACACAAAAAGAGACTTTTAGCCCTCCATAGTAGCCCAGTTTGCAAT
GTGTTATTAATTCGGTATGTAGCATTCCACTAGGGAATTCAAAGATGCATAAGAAATCATTCTAGATTTCTTGTCCATTTTGGAATTTTCCACAGATAGAAGCTGT
GTCGACCGCCTAATTAACCTGTTGCATGTTGGAAATGTTGTGTTTCTCTTGGTGAGGCTTCCTCACTGTCATCTTTTTGTTCTCTTTGCTATAAAGTGATGGGGAA
GGCTTGGAATGCTTTTTACTGTTGCTCAGGAATCGTTTTATGCTAGCTAAGCATGCAACTTCCATTTCCTGCATGTCTCCTACAGGTCAAAGACCATTACAACAAA
CTGATTATCAGCATGATGGGCTTTTATGGCCAACTTCAGAAGATGATCCCTTACCAAAGTTACCTTCCATCTACAAAATTCTAGTACAAAAAATACCCTGAACAGT
TTTTATTGCAATATGTTGTGATGGAGTTTGACCATATTTCATGTATCCAGAGATTTTATCCAACCTTGGATCTCAGTTGATTTTAAATTCAAGTTTCTCTTATTTG
GAAATACATGGAAATAGGAATTGCTAGTGATCCCTTTCACCATTTACGTGGG 
 
 
               AGCATG   FOX weak site 
               TGCATG   FOX strong site 
               TGCT     MBNL strong site 
              CGCT     MBNL Medium site  
               TGCC     Weak MBNL site 
               GT       ESRPs SITE 
               tCtt     PTB SITE 
 
TGCAGGAAGAAACTACCCAACTGCAGGAAGAAACTACCCAAAGCTACAATCAGCAATGTATATACGTTTTCCCTATTAGAATGATTTTTGTCCACAAGATTTCTGT
TACAAAGAGAAAAATCAATGAGCTGACTAGTGTCATCCATATAAATATTTGACCAGAGATGTATGGTGAAGGGTGTATTGAATATGACAATGAAACAATGCAGTGG
CTGTTCATTGTTGGTTGACTGAAAGTGGTCTGTTTGTAAACAAGCCACTAGTAGAAGGCAGATTAAAATTTGAGATGTTCTGTTGTTTGGCTCTTATACACAAAAC
TGTAAAATTGACTAAATACCTTGCTTCCTTGTAG 
 
TGTGGTTTCTTCAAGAGAAATAAGAAAGATCATTATGATGCCACATATCACAAGGCTGAGATCCATGCTCAGCCATCTGATAAAGAGAGGCTTACTTCTGATGCAT
AGTATTGATCTACTTCTGTAATTG 
 
GTAATTGATCAATGTTTTTTAATTGCTAGCTGTGGGACCCGCTATGGTTGTGGTGGCTAACTTTAAGAACAACAGCTTGCTATGTGTGTCCCATTAACAGATGTTT
CCAAATGTCCACACTGGCTTGCCTTGCTTGGATTTGTTTTATTTTATTTCACTTGAAAGCTCAGTTTTTGTTTTTTTTAATGCACAGTCTTTCGTTGCAGGTGAGT
TATTTTATGTTCTTGTTAAATATCTACCACAGCAATGAAGAAAATTTGCAATATTTGTACACACAAAAAGAGACTTTTAGCCCTCCATAGTAGCCCAGTTTGCAAT
GTGTTATTAATTCGGTATGTAGCATTCCACTAGGGAATTCAAAGATGCATAAGAAATCATTCTAGATTTCTTGTCCATTTTGGAATTTTCCACAGATAGAAGCTGT
GTCGACCGCCTAATTAACCTGTTGCATGTTGGAAATGTTGTGTTTCTCTTGGTGAGGCTTCCTCACTGTCATCTTTTTGTTCTCTTTGCTATAAAGTGATGGGGAA
GGCTTGGAATGCTTTTTACTGTTGCTCAGGAATCGTTTTATGCTAGCTAAGCATGCAACTTCCATTTCCTGCATGTCTCCTACAGGTCAAAGACCATTACAACAAA
CTGATTATCAGCATGATGGGCTTTTATGGCCAACTTCAGAAGATGATCCCTTACCAAAGTTACCTTCCATCTACAAAATTCTAGTACAAAAAATACCCTGAACAGT
TTTTATTGCAATATGTTGTGATGGAGTTTGACCATATTTCATGTATCCAGAGATTTTATCCAACCTTGGATCTCAGTTGATTTTAAATTCAAGTTTCTCTTATTTG
GAAATACATGGAAATAGGAATTGCTAGTGATCCCTTTCACCATTTACGTGGG 
 
 
               AGCATG   FOX weak site 
               TGCATG   FOX strong site 
               TGCT     MBNL strong site 
               CGCT     MBNL Medium site  
               TGCC     Weak MBNL site 
               GT       ESRPs SITE 
               tCtt     PTB SITE 
 
UCU?
UGCU?
UGCAUG?
ESRP MBNL
UGU
-331 +900
-3671 +2189
PTBP
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To summarise, this chapter established the gold model of an ITGA6 minigene, which 
allowed us to investigate how the ITGA6 alternative exon can be regulated. MBNL1 
and PTB were the factors that regulated ITGA6 alternative exon both endogenously 
and in the minigene. Furthermore, PTB, which is a novel regulatory factor for the 
ITGA6 alternative exon, was identified to bind downstream of the alternative exon and 
yet to repress the alternative exon. By deleting the candidate-binding sites, PTB was 
shown to activate the alternative exon through these downstream sites. The exact 
mechanism through which PTB can repress ITGA6 alternative exon was not identified; 
however, several hypotheses exist for how PTB can regulate alternative splicing, 
including through binding to specific individual binding sites to control exon inclusion, 
or through the indirect repression via interaction with other regulatory proteins, of 
which our data would support the latter model. We predict that PTB interacts with 
other regulatory proteins, whether MBNL1 or RBFOX2, to indirectly regulate ITGA6 
alternative exon, as well as through direct binding to the downstream binding sites. 
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Alternative splicing is now widely considered an important mechanism for controlling gene 
expression in the eukaryotic cells.  During cell differentiation, gene expression can be 
changed in different ways, including alternative splicing.  Recently, abnormal alternative 
splicing has been reported to play a major role in causing some serious conditions, including 
cancer, infertility, muscular and neurological disease.  Alternative splicing occurs via 
regulatory proteins, each of which has a specific mechanism.  In this thesis, I have focused 
on studying alternative splicing mechanisms in depth.   
 
To enable investigation of fundamentally important alternative splicing mechanisms, it is 
important to find a gene which has an important function in development and has been 
conserved across many species during evolution.  I started my project by using data from 
(Venables et al., 2013b), who discovered alternative splicing events conserved across the 
evolutionary tree for 10 genes, including PLOD2, CLSTN1, ATP2A1, PALM, KIF13A, FMNL3, 
PPIP5K1, MARK2, FNIP1 and ITGA6, which are all important in stem cell biology.  As these 
alternative splicing events have been conserved, they are likely to be extremely important in 
the cell differentiation and body plan development of all vertebrates, including humans; 
thus, these events probably also have medical significance.  I investigated the above genes 
in early zebrafish development to find alternative splicing events with regulation 
mechanisms that have been conserved between fish and humans.  I found that zebrafish 
integrin α6 (ITGA6) and kinesin family member 13A (KIF13A) had alternative splicing 
mechanisms that differed between the head and tail after fertilization of the egg.  However, 
in my research, ITGA6 was the only gene which changed its splicing pattern during the 
course of embryonic development.  This result suggested that ITGA6 was an appropriate 
gene on which to focus the majority of my study of alternative splicing mechanisms.  
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ITGA6 belongs to the integrin family, which is a group of dimeric cell surface proteins that 
are each composed of an alpha and a beta chain.  Due to ancient gene duplication, ITGA6 
has three mammalian paralogues, including ITGA3 and ITGA7.  I found that ITGA6 has five 
paralogues in zebrafish.  The presences of two alternative C-terminals isoforms of ITGA6 are 
conserved among all vertebrate, even in zebrafish.  Five paralogues of ITGA6 were seen in 
the zebrafish head and tail during development after fertilization; only ITGA6A and ITGA6B 
showed similar alternative splicing patterns, suggesting that they may have similar functions.   
 
ITGA6 splicing patterns in human cancer cell lines were determined to see if they were 
similar to the different splicing profiles observed in zebrafish and stem cell development. 
These studies indicated important differences in splicing profiles between HeLa, MCF7 and 
MDA-MB-231 cells. These might be important. Some studies have reported that ITGA6A and 
ITGA6B have the same function in mouse embryogenesis.  However, there is evidence that 
the ITGA6 A and B isoforms have different functions in cancer stem cells.  In cancer, ITGA6 
may be necessary for the tumorigenicity of a stem cell–like population within the MCF-7 cell 
line (Cariati et al., 2008), and ITGA6 may also regulate glioblastoma stem cell differentiation 
(Lathia et al. 2010).  High ITGA6 expression is a biomarker in breast cancer cells.  
 
Alternative splicing mechanisms of ITGA6 within cancer cell lines was also studied to 
understand how they are regulated.  Alternative splicing of ITGA6 creates two different 
cytoplasmic C-termini in fibroblasts and stem cells (Cooper et al., 1991, Tamura et al., 1991).  
It has already been shown that ITGA6 exon 25 is under the control of three separate splicing 
factors.  In two parallel studies of alternative splicing during stem cell differentiation, Ben 
Blencowe’s laboratory showed that the knockdown of the splicing regulatory factor MBNL1 
increases the efficiency of stem cell differentiation (Han et al., 2013), and Venables et al. 
showed that the MBNL1 and RBFOX2 splicing regulatory factors enhance the inclusion of the 
ITGA6 exon 25 in fibroblasts (Venables et al., 2013) . A recent study showed that the 
epithelial splicing regulatory protein (ESRP) enhances the inclusion of this exon as well (Goel 
et al., 2014).  
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We aimed to examine these regulation factors and try to identify others using cancer cell 
lines.  We confirmed that the MBNL1, RBFOX2 and ESRP regulatory factors activate the 
inclusion of the alternative exon 25 of ITGA6 in breast and cervical cancer cell lines. 
Normally, the splicing activities of these factors are controlled according to their binding 
sites (Dredge et al., 2005; Zhang et al., 2008a; Goers et al., 2010; Llorian et al., 2010).  
MBNL1, RBFOX and ESRP enhance exon inclusion when they bind downstream of the exon 
but inhibit it when they bind upstream.  ITGA6a is involved in the proliferation of colon 
cancer cells, and ITGA6b is involved in cancer stem cell function by means of a feedback 
loop involving VEGF.  If ITGA6 is repressed by the ESRP factor, it might also be repressed by 
MBNL1, RBFOX or PTBP, which could affect VEGF signalling.  
 
After confirming the activating effects of the above splicing factors in cancer cell lines, we 
hoped to identify a novel regulation factor that represses the ITGA6 alternative exon 25. We 
identified PTB as a novel regulator of this splicing event.  Polypyrimidine tract-binding 
protein (PTBP) is known to be a repressive splicing factor.  Experiments involving the siRNA 
knockdown of PTBP in breast cancer cell lines strongly reduced the skipping of exon 25 from 
ITGA6, indicating that PTBP is inhibitory.  This is in direct contrast to ITGA6 alternative exon 
25 being activated by MBNL1, RBFOX and ESRP.   
 
It was important to understand how these RNA splicing regulators regulate alternative 
splicing of ITGA6.  Consequently, we aimed to identify the PTBP binding site and examine 
how it can regulate the inclusion of the ITGA6 alternative exon 25.  PTBP usually binds at 
pyrimidine-rich motifs in the RNA, such as UCUU or CUCUCU, and binds upstream of the 
alternative exon (near the 3’ splice site) to act as a repressor.  The hypothesis was that if 
PTBP binds downstream, it may still function as a repressor of the ITGA6 alternative exon 25, 
perhaps by interacting with other regulatory factors.  To test this hypothesis, I established a 
minigene for the ITGA6 alternative exon 25 with introns surrounding it upstream and 
downstream.  This 1.3-kb ITGA6 minigene behaved as if it were endogenous in terms of 
splicing control, showing inhibition by PTBP and activation by MBNL1.  Two candidate 
binding sites for PTBP were identified, both downstream. However, mutagenesis of these 
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PTBP candidate binding sites reduced the inclusion of the ITGA6 alternative exon 25. This 
means that PTBP is actually activating this exon through direct RNA binding, even though it 
has an overall repressive effect.  Studies have shown that PTBP can repress alternative exon 
splicing via interaction with other regulatory factors, including RAVER1 (Gromak et al., 2003), 
MRG15 (Luco et al., 2010) and NOVA1 and NOVA2 (Polydorides et al., 2000). PTB might thus 
be indirectly repressing splicing of the ITGA6 exon through protein-protein interactions, 
possibly with MBLN or RBFOX, to inhibit the splicing activity of these proteins. 
 
Given the finding that the PTBP binding sites are located downstream of the ITGA6 
alternative exon 25 within a cluster of binding sites for other proteins, including MBNL1, 
RBFOX, ESRP and PTB suggested in two hypotheses. One hypothesis is that PTB   binding 
downstream of the alternative exon can repress alternative exon splicing via direct binding 
to RNA. This was proven not to be the case. In fact, PTB binding downstream of the 
regulated exon seemed to weakly enhance this exon, similarly to other examples of PTB 
splicing regulation. The alternative hypothesis was that PTB might repress ITGA6 splicing 
through indirect interactions. In this case and we suggest PTB interacts with regulatory 
proteins such as MBNL1 that normally activate the inclusion of the alternative exon 25, and 
this interaction prevents MBLN from functioning properly (Figure 5.1). Supporting this 
hypothesis, MBNL1 protein interactions with PTBP have been reported (Gooding et al., 
2013).   
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To conclude, the research has demonstrated the principle of combinatorial regulation of alternative 
splicing in ITGA6. We found that the ITGA6 alternative splicing mechanism is conserved across 
evolutionary history.  I confirmed that the ITGA6 alternative exon 25 is activated by RBFOX, MBNL1 
and ESRP in cancer cell lines as well as stem cells and fibroblasts.  PTBP was identified as a novel 
regulatory factor for ITGA6 and also found the sequence in ITGA6 through which the repression of 
alternative splicing by PTBP occurs.  I also developed a hypothesis for how ITGA6 may be regulated 
by PTBP and MBNL1 in cancer cell lines. The findings regarding PTBP regulation of alternative splicing 
by interacting with other proteins will prove an exciting basis for further research.   
 
 
 
 Figure 5.1 Schematic illustrate the two hypotheses of how ITGA6 alterntive exon  25 
regulated . a)  Possible mechanism for splicing regulation factors to control the ITGA6 
exon (blue box). In this model, PTB ( bright violet) interact with MBNL ( green)  and 
prevents MBLN from activating the alternative exon. b) A further possibility is that PTB   
binding downstream of the alternative exon could repress its splicing via direct binding 
to RNA. 
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